<SEC-DOCUMENT>0001654954-25-010214.txt : 20250829
<SEC-HEADER>0001654954-25-010214.hdr.sgml : 20250829
<ACCEPTANCE-DATETIME>20250829161651
ACCESSION NUMBER:		0001654954-25-010214
CONFORMED SUBMISSION TYPE:	S-8
PUBLIC DOCUMENT COUNT:		26
FILED AS OF DATE:		20250829
DATE AS OF CHANGE:		20250829
EFFECTIVENESS DATE:		20250829

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		S-8
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-289945
		FILM NUMBER:		251281105

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-8
<SEQUENCE>1
<FILENAME>cvm_s8.htm
<DESCRIPTION>FORM S-8
<TEXT>
<html><head><title>cvm_s8.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="font-size:1px;width:100%"> <tr > <td style="BORDER-BOTTOM: 5px solid;"></td></tr> <tr > <td style="BORDER-BOTTOM: 2px solid;"></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Washington, D.C. 20549</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><font style="font-size:18pt">FORM S-8</font></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">REGISTRATION STATEMENT</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Under the Securities Act of l933</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:60%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid;"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong><font style="font-size:18pt">CEL-SCI CORPORATION</font></strong></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px 0px 0px 0in">(Exact name of issuer as specified in its charter)</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;text-align:left;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;width:45%;"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>Colorado</strong></p></td> <td style="width:10%;"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>&nbsp;</strong></p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:45%;"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>84-0916344</strong></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px">(State or other jurisdiction of</p> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px">incorporation or organization)</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px">(I.R.S. Employer</p> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px">Identification No.)</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>8229 Boone Blvd., Suite 802</strong></p> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>Vienna, Virginia</strong></p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>&nbsp;</strong></p></td> <td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>22182</strong></p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px">(Address of Principal Executive Offices)</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px">(Zip Code)</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2025 Non-Qualified Stock Option Plan</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2025 Stock Bonus Plan</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">_______________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:center;">(Full Title of Plan)</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Geert R. Kersten</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">CEL-SCI Corporation</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">8229 Boone Blvd., Suite 802</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><u>Vienna, Virginia 22182</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(Name and address of agent for service)</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><u>(703) 506-9460</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(Telephone number, including area code, of agent for service)</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Copies of all communications, including all communications sent to agent for service to:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">William T. Hart, Esq.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Hart &amp; Hart</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">l624 N. Washington Street</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Denver, Colorado&nbsp; 80203</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(303) 839-0061</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b2 of the Exchange Act.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;text-align:left;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"> <tr style="height:15px"> <td style="width:30%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Large accelerated filer </p></td> <td style="width:20%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td> <td style="width:30%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Accelerated filer </p></td> <td style="width:20%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Non-accelerated filer </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9746;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Smaller reporting company </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9746;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Emerging growth company </p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 7(a)(2)(B) of the Securities Act. &#9744;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="font-size:1px;width:100%"> <tr > <td style="BORDER-BOTTOM: 2px solid;"></td></tr> <tr > <td style="BORDER-BOTTOM: 5px solid;"></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CEL-SCI CORPORATION</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Cross Reference Sheet Required Pursuant to Rule 404</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">PART I</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:6%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(NOTE:</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Pursuant to instructions to Form S-8, the Prospectus described below is not required to be filed with this Registration Statement.)</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;text-align:justify;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">Item No.</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;" colspan="2"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">Form S-8 Caption</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">Caption in Prospectus</p></td></tr> <tr style="height:15px"> <td style="width:7%;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:3%;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:45%;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:2%;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">1.</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">Plan Information</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">(a)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">General Plan Information</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Stock Option and Bonus Plan</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">(b)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">Securities to be Offered</p></td> <td></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Stock Option and Bonus Plan</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">(c)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">Employees who may Participate in the Plans</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Stock Option and Bonus Plan</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">(d)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px 0px 0px 0in">Purchase of Securities Pursuant to the Plans and Payment for Securities Offered</p></td> <td></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Stock Option and Bonus Plan</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">(e)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">Resale Restrictions</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">Resale of Shares by Affiliates</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">(f)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px 0px 0px 0in">Tax Effects of Plan Participation</p></td> <td></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Stock Option and Bonus Plan</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">(g)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">Investment of Funds</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">Not Applicable.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">(h)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">Withdrawal from the Plan; Assignment of Interest</p></td> <td></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px">Other Information Regarding the Plans</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">(i)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">Forfeitures and Penalties</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px 0px 0px 0in">Other Information Regarding the Plans</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">(j)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">Charges and Deductions and Liens Therefore</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px">Other Information Regarding the Plans</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">2.</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">Registrant Information and Employee </p> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 15px">Plan Annual Information</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px">Available Information, Documents </p> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px 0px 0px 15px">Incorporated by Reference</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:center;">PART II</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:center;">INFORMATION REQUIRED IN REGISTRATION STATEMENT</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><u>Item 3 - Incorporation of Documents by Reference</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">The following documents filed with the Commission by CEL-SCI (Commission File No. 001-11889) are incorporated by reference into this prospectus:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our Annual Report on Form 10-K for the fiscal year ended September 30, 2024;</td></tr> <tr style="height:15px"> <td></td> <td></td> <td></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our quarterly reports on Form 10-Q for the periods ended December 31, 2024 and March 31, 2025 and June 30, 2025;</td></tr> <tr style="height:15px"> <td></td> <td></td> <td></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our current reports on Form 8-K filed with the SEC on November 13, 2024, November 15, 2024, December 31, 2024, March 18, 2025, May 19, 2025, May 23, 2025, July 14, 2025 and August 22, 2025;</td></tr> <tr style="height:15px"> <td></td> <td></td> <td></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our Proxy Statement relating to our May 19, 2025 Annual Meeting of Shareholders; and</td></tr> <tr style="height:15px"> <td></td> <td></td> <td></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the description of our common stock contained in our Registration Statement on Form 8-A filed with the SEC on July 2, 1996 and all amendments and reports updating that description.</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">All documents filed with the Commission by CEL-SCI pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of this registration statement and prior to the termination of this offering shall be deemed to be incorporated by reference into this registration statement and to be a part of this registration statement from the date of the filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference shall be deemed to be modified or superseded for the purposes of this registration statement to the extent that a statement contained in this registration statement or in any subsequently filed document which also is or is deemed to be incorporated by reference in this registration statement modifies or supersedes such statement. Such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">Investors are entitled to rely upon information in this registration statement or incorporated by reference at the time it is used by CEL-SCI to offer and sell securities, even though that information may be superseded or modified by information subsequently incorporated by reference into this registration statement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><u>Item 4 - Description of Securities</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">Not required.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><u>Item 5 - Interests of Named Experts and Counsel</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">Not Applicable.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><u>Item 6 - Indemnification of Directors and Officers</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">The Bylaws of the Company provide in substance that the Company shall indemnify any person who was or is a party or is threatened to be made a party to any threatened or completed action, suit or proceeding, whether civil, criminal, administrative, or investigative by reason of the fact that such person is or was a director, officer, employee, fiduciary or agent of the Company, or is or was serving at the request of the Company as a director, officer, employee, fiduciary or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorney's fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person to the full extent permitted by the laws of the state of Colorado; and that expenses incurred in defending any such civil or criminal action, suit or proceeding may be paid by the Company in advance of the final disposition of such action, suit or proceeding as authorized by the Board of Directors in the specific case upon receipt of an undertaking by or on behalf of such indemnified person to repay such amount to the Company unless it shall ultimately be determined that such person is entitled to be indemnified by the Company as authorized in the Bylaws.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><u>Item 7 &#8211; Exemption for Registration Claimed</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Not applicable.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><u>Item 8 - Exhibits</u>&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px;background-color:#cceeff"> <td style="width:5%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">4&nbsp;-</p></td> <td style="width:40%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Instruments Defining Rights of Security Holders</p></td> <td style="width:2%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(a) -</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Common Stock</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Incorporated by reference to Exhibit 4(a) of the Company's Registration Statements on Form S-l, File Nos. 2-85547-D and 33-7531.</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">(b) -</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex4b.htm">2025 Non-Qualified Stock Option Plan</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">(c) -</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex4c.htm">2025 Stock Bonus Plan</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">5 -</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex5.htm">Opinion Regarding Legality</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">l5 -</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">Letter Regarding Unaudited Interim&nbsp;Financial Information</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">None</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">23 -</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in"><a href="cvm_ex232.htm">Consent of Independent Public&nbsp;Accountants and Attorneys</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">24 -</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#po">Power of Attorney</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Included in the signature page of this Registration Statement</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">99 -</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex99.htm">Additional Exhibits</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Re-offer Prospectus</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">107 &#8211;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex107.htm">Filing Fee Table</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><u>Item 9 - Undertakings</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">(a) The undersigned registrant hereby undertakes:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:12%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(i)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">to include any prospectus required by Section l0(a)(3) of the Securities Act of l933;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(ii)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(iii)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change in such information in the registration statement.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Provided, however, that paragraphs (a)(l)(i) and (a)(l)(ii) will not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed by the registrant pursuant to Section l3 or Section l5(d) of the Securities Act of l934.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(2) That, for the purpose of determining any liability under the Securities Act of l933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">(b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of l933, each filing of the registrant's Annual Report pursuant to Section l3(a) or Section l5(d) of the Securities Exchange Act of l934 (and, where applicable, each filing of any employee benefit plan's annual report pursuant to Section l5(d) of the Securities Exchange Act of l934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">(c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0in; text-align:center;"><strong><a name="po">POWER OF ATTORNEY</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">KNOW ALL MEN BY THESE PRESENTS, that each of the undersigned constitutes and appoints Geert R. Kersten, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or his substitutes or substitute may lawfully do or cause to be done by virtue hereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SIGNATURES</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">Pursuant to the requirements of the Securities Act of l933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Vienna, Virginia, on August 29, 2025.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>CEL-SCI CORPORATION</strong></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:50%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:3%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:35%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:12%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">By:</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">/s/Geert R. Kersten&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Geert R. Kersten, Principal Executive and Accounting Officer</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">By:</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">/s/Patricia Prichep</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Patricia Prichep, Principal Financial and Operations Officer</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">Pursuant to the requirements of the Securities Act of l933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;width:30%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">Signature</p></td> <td style="width:5%;"></td> <td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px 0px 0px 0in">Title</p></td> <td style="width:5%;"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:30%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px">Date</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">/s/Geert R. Kersten</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">Director,</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">August 29, 2025</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Geert R. Kersten</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">/s/Robert Watson</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">Director</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">August 29, 2025</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Robert Watson</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">/s/Bruno Baillavoine</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">Director, Chairman of the Board</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">August 29, 2025</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Bruno Baillavoine</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>FORM S-8</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CEL-SCI Corporation</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>8229 Boone Blvd.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Suite 802</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Vienna, Virginia 22182</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>EXHIBITS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.(B)
<SEQUENCE>2
<FILENAME>cvm_ex4b.htm
<DESCRIPTION>2025 NON-QUALIFIED STOCK OPTION PLAN
<TEXT>
<html><head><title>cvm_ex4b.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>EXHIBIT 4(b)</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>CEL-SCI CORPORATION</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2025 NON-QUALIFIED STOCK OPTION PLAN</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">l. <u>Purpose</u>. This Non-Qualified Stock Option Plan (the "Plan") is intended to advance the interests of CEL-SCI Corporation (the &#8220;Company&#8221;) and its shareholders, by encouraging and enabling selected officers, directors, consultants and key employees upon whose judgment, initiative and effort the Company is largely dependent for the successful conduct of its business, to acquire and retain a proprietary interest in the Company by ownership of its stock. Options granted under the Plan are intended to be Options which do not meet the requirements of Section 422 of the Internal Revenue Code of 1954, as amended (the "Code").</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">2. <u>Definitions</u>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">(a) "Board" means the Board of Directors of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">(b) "Committee" means the directors duly appointed to administer the Plan.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">(c) "Common Stock" means the Company's Common Stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">(d) "Date of Grant" means the date on which an Option is granted under the Plan.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">(e) "Option" means an Option granted under the Plan.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">(f) "Optionee" means a person to whom an Option, which has not expired, has been granted under the Plan.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">(g) "Successor" means the legal representative of the estate of a deceased optionee or the person or persons who acquire the right to exercise an Option by bequest or inheritance or by reason of the death of any Optionee.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">3. <u>Administration of Plan</u>. The Plan shall be administered by the Company's Board of Directors or in the alternative, by a committee of two or more directors appointed by the Board (the "Committee"). If a Committee should be appointed, the Committee shall report all action taken by it to the Board. The Committee shall have full and final authority in its discretion, subject to the provisions of the Plan, to determine the individuals to whom and the time or times at which Options shall be granted and the number of shares and purchase price of Common Stock covered by each Option; to construe and interpret the Plan; to determine the terms and provisions of the respective Option agreements, which need not be identical, including, but without limitation, terms covering the payment of the Option Price; and to make all other determinations and take all other actions deemed necessary or advisable for the proper administration of the Plan. All such actions and determinations shall be conclusively binding for all purposes and upon all persons.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">4. <u>Common Stock Subject to Options</u>. The aggregate number of shares of the Company's Common Stock which may be issued upon the exercise of Options granted under the Plan shall not exceed 116,667. The shares of Common Stock to be issued upon the exercise of Options may be authorized but unissued shares, shares issued and reacquired by the Company or shares bought on the market for the purposes of the Plan. In the event any Option shall, for any reason, terminate or expire or be surrendered without having been exercised in full, the shares subject to such Option but not purchased thereunder shall again be available for Options to be granted under the Plan.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">1</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">5. <u>Participants</u>. Options may be granted under the Plan to employees, directors and officers, and consultants or advisors to the Company (or the Company&#8217;s subsidiaries), provided however that bona fide services shall be rendered by such consultants or advisors and such services must not be in connection with the offer or sale of securities in a capital-raising transaction and must not involve, directly or indirectly, the promotion or maintenance of a market for the Company&#8217;s securities.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">6. <u>Terms and Conditions of Options</u>. Any Option granted under the Plan shall be evidenced by an agreement executed by the Company and the recipient and shall contain such terms and be in such form as the Committee may from time to time approve, subject to the following limitations and conditions:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 90px; text-align:justify;">(a) <u>Option Price</u>. The Option Price per share with respect to each Option shall be determined by the Committee. The option price of any options granted pursuant to the Plan may not be changed, except in the case of stock splits, reorganizations or recapitalizations.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 90px; text-align:justify;">(b) <u>Period of Option</u>. The period during which each option may be exercised, and the expiration date of each Option shall be fixed by the Committee, but, notwithstanding any provision of the Plan to the contrary, such expiration date shall not be more than ten years from the date of Grant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 90px; text-align:justify;">(c) <u>Vesting of Shareholder Rights</u>. Neither an Optionee nor his successor shall have any rights as a shareholder of the Company until the certificates evidencing the shares purchased are properly delivered to such Optionee or his successor.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 90px; text-align:justify;">(d) <u>Exercise of Option</u>. Each Option shall be exercisable from time to time during a period (or periods) determined by the Committee, and ending upon the expiration or termination of the Option; provided, however, (1) the Committee may, by the provisions of any Option Agreement, limit the number of shares purchasable thereunder in any period or periods of time during which the Option is exercisable, and (2) no option may be exercised until one year after the date of grant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 90px; text-align:justify;">(e) <u>Nontransferability of Option</u>. No Option shall be transferable or assignable by an Optionee, otherwise than by will or the laws of descent and distribution and each Option shall be exercisable, during the Optionee's lifetime, only by him. No Option shall be pledged or hypothecated in any way and no Option shall be subject to execution, attachment, or similar process except with the express consent of the Committee.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 90px; text-align:justify;">(f) <u>Death of Optionee.</u> In the event of the death of an Optionee, all unvested options will vest and an option theretofore granted to the Optionee shall be exercisable only by the person or persons to whom the Optionee&#8217;s rights under the option shall pass by the Optionee&#8217;s will or by the laws of descent and distribution.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 90px; text-align:justify;">(g) <u>Payment for Options</u>. The Company is not required to pay cash for an option under any circumstances.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">7. <u>Reclassification, Consolidation, or Merger</u>. If and to the extent that the number of issued shares of Common Stock of the Corporation shall be increased or reduced by change in par value, split up, reclassification, distribution of a dividend payable in stock, or the like, the number of shares which may be issued upon the exercise of any Options which may be granted pursuant to this Plan, the number of shares issuable upon the exercise of any Option previously granted and the Exercise Price of any Option previously granted, shall be proportionately adjusted by the Committee, whose determination shall be conclusive. If the Company is reorganized or consolidated or merged with another corporation, an Optionee granted an Option hereunder shall be entitled to receive Options covering shares of such reorganized, consolidated, or merged company in the same proportion, at an equivalent price, and subject to the same conditions. The new Option or assumption of the old Option shall not give the Optionee additional benefits which he or she did not have under the old Option, or deprive him or her of benefits which he or she had under the old Option.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">8. <u>Restrictions on Issuing Shares</u>. The exercise of each Option shall be subject to the condition that if at any time the Company shall determine in its discretion that the satisfaction of withholding tax or other withholding liabilities, or that the listing, registration, or qualification of any shares otherwise deliverable upon such exercise upon any securities exchange or under any state or federal law, or that the consent or approval of any regulatory body, is necessary or desirable as a condition of, or in connection with, such exercise or the delivery or purchase of shares purchased thereto, then in any such event, such exercise shall not be effective unless such withholding, listing, registration, qualification, consent, or approval shall have been effected or obtained free of any conditions not acceptable to the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 90px; text-align:justify;">Unless the shares of stock covered by the Plan have been registered with the Securities and Exchange Commission pursuant to Section 5 of the Securities Act of l933, each optionee shall, by accepting an option, represent and agree, for himself and his transferees by will or the laws of descent and distribution, that all shares of stock purchased upon the exercise of the option will be acquired for investment and not for resale or distribution. Upon such exercise of any portion of an option, the person entitled to exercise the same shall, upon request of the Company, furnish evidence satisfactory to the Company (including a written and signed representation) to the effect that the shares of stock are being acquired in good faith for investment and not for resale or distribution. Furthermore, the Company may, if it deems appropriate, affix a legend to certificates representing shares of stock purchased upon exercise of options indicating that such shares have not been registered with the Securities and Exchange Commission and may so notify the Company's transfer agent. Such shares may be disposed of by an optionee in the following manner only: (l) pursuant to an effective registration statement covering such resale or reoffer, (2) pursuant to an applicable exemption from registration as indicated in a written opinion of counsel acceptable to the Company, or (3) in a transaction that meets all the requirements of Rule l44 of the Securities and Exchange Commission. If shares of stock covered by the Plan have been registered with the Securities and Exchange Commission, no such restrictions on resale shall apply, except in the case of optionees who are directors, officers, or principal shareholders of the Company. Such persons may dispose of shares only by one of the three aforesaid methods.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">9. <u>Use of Proceeds</u>. The proceeds received by the Company from the sale of Common Stock pursuant to the exercise of Options granted under the Plan shall be added to the Company's general funds and used for general corporate purposes.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">10. <u>Amendment, Suspension, and Termination of Plan</u>. The Board of Directors may alter, suspend, or discontinue the Plan at any time.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">Unless the Plan shall theretofore have been terminated by the Board, the Plan shall terminate ten years after the adoption of the Plan. No Option may be granted during any suspension or after the termination of the Plan. No amendment, suspension, or termination of the Plan shall, without an Optionee's consent, alter or impair any of the rights or obligations under any Option theretofore granted to such Optionee under the Plan.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">11. <u>Limitations</u>. Every right of action by any person receiving options pursuant to this Plan against any past, present or future member of the Board, or any officer or employee of the Company arising out of or in connection with this Plan shall, irrespective of the place where such action may be brought and irrespective of the place of residence of any such director, officer or employee cease and be barred by the expiration of one year from the date of the act or omission in respect of which such right of action arises.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">l2. <u>Governing Law</u>. The Plan shall be governed by the laws of the State of Colorado.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">13. <u>Expenses of Administration</u>. All costs and expenses incurred in the operation and administration of this Plan shall be borne by the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.(C)
<SEQUENCE>3
<FILENAME>cvm_ex4c.htm
<DESCRIPTION>2025 STOCK BONUS PLAN
<TEXT>
<html><head><title>cvm_ex4c.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 4(c)</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>CEL-SCI CORPORATION</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2025 STOCK BONUS PLAN</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">l. <strong><u>Purpose</u></strong>. The purpose of this Stock Bonus Plan is to advance the interests of CEL-SCI Corporation (the &#8220;Company&#8221;) and its shareholders, by encouraging and enabling selected officers, directors, consultants and key employees upon whose judgment, initiative and effort the Company is largely dependent for the successful conduct of its business, to acquire and retain a proprietary interest in the Company by ownership of its stock, to keep personnel of experience and ability in the employ of the Company and to compensate them for their contributions to the growth and profits of the Company and thereby induce them to continue to make such contributions in the future.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">2. <strong><u>Definitions</u></strong>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">A. &#8220;Board&#8221; shall mean the board of directors of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">B. &#8220;Committee&#8221; means the directors duly appointed to administer the Plan.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">C. &#8220;Plan&#8221; shall mean this Stock Bonus Plan.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">D. &#8220;Bonus Share&#8221; shall mean the shares of common stock of the Company reserved pursuant to Section 4 hereof and any such shares issued to a Recipient pursuant to this Plan.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">E. &#8220;Recipient&#8221; shall mean any individual rendering services for the Company to whom shares are granted pursuant to this Plan.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">3. <strong><u>Administration of Plan</u></strong>. The Plan shall be administered by a committee of two or more directors appointed by the Board (the &#8220;Committee&#8221;). The Committee shall report all action taken by it to the Board. The Committee shall have full and final authority in its discretion, subject to the provisions of the Plan, to determine the individuals to whom, and the time or times at which, Bonus Shares shall be granted and the number of Bonus Shares; to construe and interpret the Plan; and to make all other determinations and take all other actions deemed necessary or advisable for the proper administration of the Plan. All such actions and determinations shall be conclusively binding for all purposes and upon all persons.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">4. <strong><u>Bonus Share Reserve</u></strong>. There shall be established a Bonus Share Reserve to which shall be credited 16,667 shares of the Company&#8217;s common stock. In the event that the shares of common stock of the Company should, as a result of a stock split or stock dividend or combination of shares or any other change, or exchange for other securities by reclassification, reorganization, merger, consolidation, recapitalization or otherwise, be increased or decreased or changed into or exchanged for, a different number or kind of shares of stock or other securities of the Company or of another corporation, the number of shares then remaining in the Bonus Share Reserve shall be appropriately adjusted to reflect such action. Upon the grant of shares hereunder, this reserve shall be reduced by the number of shares so granted. Distributions of Bonus Shares may, as the Committee shall in its sole discretion determine, be made from authorized but unissued shares or from treasury shares. All authorized and unissued shares issued as Bonus Shares in accordance with the Plan shall be fully paid and non-assessable and free from preemptive rights.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">5. <strong><u>Eligibility, and Granting and Vesting of Bonus Shares</u></strong>. Bonus Shares may be granted under the Plan to the Company&#8217;s (or the Company&#8217;s subsidiaries) employees, directors and officers, and consultants or advisors to the Company (or its subsidiaries), provided however that bona fide services shall be rendered by such consultants or advisors and such services must not be in connection with the offer or sale of securities in a capital-raising transaction, or promoting the Company&#8217;s common stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">1</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 63pt; text-align:justify;">The Committee, in its sole discretion, is empowered to grant to an eligible Participant a number of Bonus Shares as it shall determine from time to time. Each grant of these Bonus Shares shall become vested according to a schedule to be established by the Committee at the time of the grant. For purposes of this plan, vesting shall mean the period during which the recipient must remain an employee or provide services for the Company. At such time as the employment of the Recipient ceases, or at such time the Recipient ceases to provide services to the Company, any shares not fully vested shall be forfeited by the Recipient and shall be returned to the Bonus Share Reserve. The Committee, in its sole discretion, may also impose restrictions on the future transferability of the bonus shares, which restrictions shall be set forth on the notification to the Recipient of the grant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">Any shares issued pursuant to the Plan will not be entitled to any dividends until any vesting requirements established by the Committee when the shares were issued have been satisfied.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">The aggregate number of Bonus Shares which may be granted pursuant to this Plan shall not exceed the amount available therefore in the Bonus Share Reserve.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">6. <strong><u>Form of Grants</u></strong>. Each grant shall specify the number of Bonus Shares subject thereto, subject to the provisions of Section 5 hereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">At the time of making any grant, the Committee shall advise the Recipient by delivery of written notice, in the form of Exhibit A hereto annexed.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">7. <strong><u>Recipients&#8217; Representations</u></strong>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">A. The Committee may require that, in acquiring any Bonus Shares, the Recipient agree with, and represent to, the Company that the Recipient is acquiring such Bonus Shares for the purpose of investment and with no present intention to transfer, sell or otherwise dispose of shares except such distribution by a legal representative as shall be required by will or the laws of any jurisdiction in winding-up the estate of any Recipient. Such shares shall be transferable thereafter only if the proposed transfer shall be permissible pursuant to the Plan and if, in the opinion of counsel (who shall be satisfactory to the Committee), such transfer shall at such time be in compliance with applicable securities laws.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">B. To effectuate Paragraph A above, the Recipient shall deliver to the Committee, in duplicate, an agreement in writing, signed by the Recipient, in form and substance as set forth in Exhibit B hereto annexed, and the Committee shall forthwith acknowledge its receipt thereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 33.75pt; text-align:justify;">8. <strong><u>Restrictions Upon Issuance</u></strong>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">A. Bonus Shares shall forthwith after the making of any representations required by Section 6 hereof, or if no representations are required then within thirty (30) days of the date of grant, be duly issued and transferred and a certificate or certificates for such shares shall be issued in the Recipient&#8217;s name. The Recipient shall thereupon be a shareholder with respect to all the shares represented by such certificate or certificates, shall have all the rights of a shareholder with respect to all such shares, including the right to vote such shares and to receive all dividends and other distributions (subject to the provisions of Sections 5 and 7(B) hereof) paid with respect to such shares. Certificates of stock representing Bonus Shares shall be imprinted with a legend to the effect that the shares represented thereby are subject to the provisions of this Agreement, and to the vesting and transfer limitations established by the Committee, and each transfer agent for the common stock shall be instructed to like effect with respect of such shares.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">B. In the event of a stock split or stock dividend or combination of shares or any other change, or exchange for other securities, by reclassification, reorganization, merger, consolidation, recapitalization or otherwise, the number of Bonus Shares available for issuance pursuant to this Plan will be proportionately adjusted by the Committee, whose determination in this regard will be final. In the event that, as the result of a stock split or stock dividend or combination of shares or any other change, or exchange for other securities, by reclassification, reorganization, merger, consolidation, recapitalization or otherwise, the Recipient shall, as owner of the Bonus Shares subject to restrictions hereunder, be entitled to new or additional or different shares of stock or securities. The certificate or certificates for, or other evidences of, such new or additional or different shares or securities, together with a stock power or other instrument of transfer appropriately endorsed, shall also be imprinted with a legend as provided in Section 7(A), and all provisions of the Plan relating to restrictions herein set forth shall thereupon be applicable to such new or additional or different shares or securities to the extent applicable to the shares with respect to which they were distributed.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">C. The grant of any Bonus Shares shall be subject to the condition that if at any time the Company shall determine in its discretion that the satisfaction of withholding tax or other withholding liabilities, or that the listing, registration, or qualification of any Bonus Shares upon such exercise upon any securities exchange or under any state or federal law, or that the consent or approval of any regulatory body, is necessary or desirable as a condition of, or in connection with, the issuance of any Bonus Shares, then in any such event, such exercise shall not be effective unless such withholding, listing, registration, qualification, consent, or approval shall have been effected or obtained free of any conditions not acceptable to the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 90px; text-align:justify;">D. Unless the Bonus Shares covered by the Plan have been registered with the Securities and Exchange Commission pursuant to Section 5 of the Securities Act of l933, each Recipient shall, by accepting a Bonus Share, represent and agree, for himself and his transferees by will or the laws of descent and distribution, that all Bonus Shares were acquired for investment and not for resale or distribution. The person entitled to receive Bonus Shares shall, upon request of the Committee, furnish evidence satisfactory to the Committee (including a written and signed representation) to the effect that the shares of stock are being acquired in good faith for investment and not for resale or distribution. Furthermore, the Committee may, if it deems appropriate, affix a legend to certificates representing Bonus Shares indicating that such Bonus Shares have not been registered with the Securities and Exchange Commission and may so notify the Company&#8217;s transfer agent. Such shares may be disposed of by a Recipient in the following manner only: (l) pursuant to an effective registration statement covering such resale or reoffer, (2) pursuant to an applicable exemption from registration as indicated in a written opinion of counsel acceptable to the Company, or (3) in a transaction that meets all the requirements of Rule l44 of the Securities and Exchange Commission. If Bonus Shares covered by the Plan have been registered with the Securities and Exchange Commission, no such restrictions on resale shall apply, except in the case of Recipients who are directors, officers, or principal shareholders of the Company. Such persons may dispose of shares only by one of the three aforesaid methods.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">9. <strong><u>Limitations</u></strong>. Neither the action of the Company in establishing the Plan, nor any action taken by it nor by the Committee under the Plan, nor any provision of the Plan, shall be construed as giving to any person the right to be retained in the employ of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Every right of action by any person receiving shares of common stock pursuant to this Plan against any past, present or future member of the Board, or any officer or employee of the Company arising out of or in connection with this Plan shall, irrespective of the place where action may be brought and irrespective of the place of residence of any such director, officer or employee cease and be barred by the expiration of one year from the date of the act or omission in respect of which such right of action arises.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">10. <strong><u>Amendment, Suspension or Termination of the Plan</u></strong>. The Board of Directors may alter, suspend, or discontinue the Plan at any time.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Unless the Plan shall theretofore have been terminated by the Board, the Plan shall terminate ten years after the adoption of the Plan. No Bonus Share may be granted during any suspension or after the termination of the Plan. No amendment, suspension, or termination of the Plan shall, without a recipient&#8217;s consent, alter or impair any of the rights or obligations under any Bonus Share theretofore granted to such recipient under the Plan.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">11. <strong><u>Governing Law</u></strong>. The Plan shall be governed by the laws of the State of Colorado.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">12. <strong><u>Expenses of Administration</u></strong>. All costs and expenses incurred in the operation and administration of this Plan shall be borne by the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>- EXHIBIT A &#8211;</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CEL-SCI CORPORATION</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">STOCK BONUS PLAN</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 33.75pt; text-align:justify;">TO:&nbsp; Recipient:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 33.75pt; text-align:justify;">PLEASE BE ADVISED that CEL-SCI Corporation has on the date hereof granted to the Recipient the number of Bonus Shares as set forth under and pursuant to the Stock Bonus Plan.&nbsp; Before these shares are to be issued, the Recipient must deliver to the Committee that administers the Stock Bonus Plan an agreement in duplicate, in the form as Exhibit B hereto.&nbsp; The Bonus Shares are issued subject to the following vesting and transfer limitations.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:40%;vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><u>Vesting</u>:</p></td> <td style="width:10%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2" style="width:40%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:12%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><u>Number of Shares</u></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2" style="vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><u>Date of Vesting</u></p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><u>Transfer Limitations</u>:</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5pt; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="font-size:10pt;font-family:times new roman;margin:0px">CEL-SCI CORPORATION</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:50%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:3%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:35%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:12%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">By:</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5pt; text-align:justify;">________________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5pt; text-align:justify;">Date</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>- EXHIBIT B &#8211;</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>CEL-SCI Corporation</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">8229 Boone Blvd. #802</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Vienna, VA 22182</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 33.75pt; text-align:justify;">I represent and agree that said Bonus Shares are being acquired by me for investment and that I have no present intention to transfer, sell or otherwise dispose of such shares, except as permitted pursuant to the Plan and in compliance with applicable securities laws, and agree further that said shares are being acquired by me in accordance with and subject to the terms, provisions and conditions of said Plan, to all of which I hereby expressly assent.&nbsp; These agreements shall bind and inure to the benefit of my heirs, legal representatives, successors and assigns.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:72%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 67.5pt">My address of record is: _________________</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 67.5pt">and my social security number: ___________</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5pt; text-align:justify;">Receipt of the above is hereby acknowledged.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Very truly yours,</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:50%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:3%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:35%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:12%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">CEL-SCI CORPORATION</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">By:</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5pt; text-align:justify;">_________________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5pt; text-align:justify;">Date</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5
<SEQUENCE>4
<FILENAME>cvm_ex5.htm
<DESCRIPTION>OPINION
<TEXT>
<html><head><title>cvm_ex5.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>EXHIBIT 5</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><em><font style="font-size:14pt">HART &amp; HART, LLC</font></em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">ATTORNEYS AT LAW</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">1624 Washington Street</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Denver, CO&nbsp; 80203</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:40%;"> <p style="margin:0px">William T. Hart, P.C.</p></td> <td> <p style="text-align:center;margin:0px">_______________</p></td> <td style="width:40%;"> <p style="text-align:right;margin:0px">Email: harttrinen@aol.com</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">Will Hart&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="text-align:right;margin:0px">Facsimile:&nbsp; (303) 839-5414&nbsp; </p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px 0px 0px 0in">(303) 839-0061</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">August 29, 2025</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">CEL-SCI Corporation</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">8229 Boone Blvd., Suite 802</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">Vienna, Virginia 22182</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">This letter will constitute an opinion upon the legality of the sale by CEL-SCI Corporation, a Colorado corporation, of up to 133,334 shares of the Company&#8217;s common stock, all as referred to in the Registration Statement on Form S-8 filed by the Company with the Securities and Exchange Commission.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">We have examined the Articles of Incorporation, the Bylaws and the minutes of the Board of Directors of the Company and the applicable laws of the State of Colorado, and a copy of the Registration Statement. In our opinion, the Company has duly authorized the issuance of the shares of stock mentioned above and such shares when sold, will be legally issued, fully paid, and non-assessable.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">Very truly yours,</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:50%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:3%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:35%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:12%;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px 0px 0px 0in">HART &amp; HART</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">By</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="margin:0px">/s/ William T. Hart</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">William T. Hart</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>cvm_ex231.htm
<DESCRIPTION>CONSENT
<TEXT>
<html><head><title>cvm_ex231.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 23.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CONSENT OF ATTORNEYS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Reference is made to the Registration Statement of CEL-SCI Corporation on Form S-8 whereby the Company proposes to sell up to 133,334 shares of the Company&#8217;s Common Stock. Reference is also made to Exhibit 5 included in the Registration Statement relating to the validity of the securities proposed to be issued and sold.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">We hereby consent to the use of our opinion concerning the validity of the securities proposed to be issued and sold.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Very Truly Yours,</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">HART &amp; HART LLC</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:50%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:3%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:35%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:12%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">By</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ William T. Hart</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">William T. Hart</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Denver, Colorado</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">August 29, 2025</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>6
<FILENAME>cvm_ex232.htm
<DESCRIPTION>CONSENT
<TEXT>
<html><head><title>cvm_ex232.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 23.2</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Consent of Independent Registered Public Accounting Firm</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">CEL-SCI Corporation</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Vienna, Virginia</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We hereby consent to the incorporation by reference in this Registration Statement of our report dated January 13, 2025, relating to the financial statements of CEL-SCI Corporation (the Company)&nbsp;appearing in the Company&#8217;s Annual Report on Form 10-K for the year ended September 30, 2024. Our report contains an explanatory paragraph regarding the Company&#8217;s ability to continue as a going concern.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>/s/ BDO USA, P.C.</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Potomac, Maryland</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">August 29, 2025</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>7
<FILENAME>cvm_ex99.htm
<DESCRIPTION>ADDITIONAL EXHIBITS
<TEXT>
<html><head><title>cvm_ex99.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 99</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CEL-SCI CORPORATION</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Common Stock</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">This Prospectus relates to shares (the "Shares") of common stock (the "Common Stock") of CEL-SCI Corporation which may be issued pursuant to certain employee compensation plans adopted by CEL-SCI. The employee compensation plans provide for the grant, to selected employees of CEL-SCI and other persons, of either shares of CEL-SCI&#8217;s common stock or options to purchase shares of CEL-SCI&#8217;s common stock. Persons who received Shares pursuant to the Plans and who are offering such shares to the public by means of this Prospectus are referred to as the "Selling Shareholders".</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Bonus Plans, Stock Compensation Plans and a 2014 Incentive Stock Bonus Plan. In some cases these plans are collectively referred to as the "Plans". The terms and conditions of any stock grants and the terms and conditions of any options, including the price of the shares of Common Stock issuable on the exercise of options, are governed by the provisions of the respective Plans and any particular agreements between CEL-SCI and the Plan participants.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The Selling Shareholders may offer the shares from time to time in negotiated transactions through the NYSE American Exchange, at fixed prices which may be changed from time to time, at market prices prevailing at the time of sale, at prices related to such prevailing market prices or at negotiated prices. The Selling Shareholders may effect such transactions by selling the Shares to or through securities broker/dealers, and such broker/dealers may receive compensation in the form of discounts, concessions, or commissions from the Selling Shareholders and/or the purchasers of the Shares for whom such broker/dealers may act as agent or to whom they sell as principal, or both (which compensation as to a particular broker/dealer might be in excess of customary commissions). See "Selling Shareholders" and "Plan of Distribution".</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">None of the proceeds from the sale of the Shares by the Selling Shareholders will be received by CEL-SCI. CEL-SCI has agreed to bear all expenses of registering the Shares with the Securities and Exchange Commission (other than underwriting discounts, selling commissions and fees and expenses of counsel and other advisers to the Selling Shareholders).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Effective May 20, 2025, CEL-SCI completed a 1-for-30 reverse stock split of its outstanding common stock (&#8220;Reverse Stock Split&#8221;). The reverse stock split did not reduce the number of authorized shares of its common stock or preferred stock. All share and per share amounts in this prospectus and in the 10-Q&nbsp;for the period ended June 30, 2025&nbsp;have been adjusted to give effect to the reverse stock split. However,&nbsp;all other&nbsp;documents incorporated by reference, including the financial statements for prior periods, do not reflect the Reverse Stock Split.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>The purchase of the securities offered by this prospectus involves a high degree of risk. Risk factors include the lack of revenues and history of loss, need for additional capital and need for FDA approval. See the &#8220;Risk Factors&#8221; section of this prospectus beginning on page 15.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or has passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">The date of this Prospectus is August __, 2025.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">1</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>AVAILABLE INFORMATION</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI is subject to the information requirements of the Securities Exchange Act of 1934 (the "Exchange Act") and in accordance therewith, files reports and other information with the Securities and Exchange Commission (the "Commission"). Proxy statements, reports and other information concerning CEL-SCI is available at the Internet Web Site maintained by the Securities and Exchange Commission at www.sec.gov. This Prospectus does not contain all information set forth in the Registration Statement of which this Prospectus forms a part and exhibits thereto which CEL-SCI has filed with the Commission under the Securities Act and to which reference is hereby made.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>DOCUMENTS INCORPORATED BY REFERENCE</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following documents filed with the Commission by CEL-SCI (Commission File No. 001-11889) are incorporated by reference into this prospectus:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our Annual Report on Form 10-K for the fiscal year ended September 30, 2024;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our quarterly reports on Form 10-Q for the periods ended December 31, 2024 and March 31, 2025and June 30, 2025;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our current reports on Form 8-K filed with the SEC on November 13, 2024, November 15, 2024, December 31, 2024, March 18, 2025, May 19, 2025, May 23, 2025, July 14, 2025, and August 22, 2025;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our Proxy Statement relating to our May 19, 2025 Annual Meeting of Shareholders; and</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the description of our common stock contained in our Registration Statement on Form 8-A filed with the SEC on July 2, 1996 and all amendments and reports updating that description.</td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI will provide, without charge, to each person to whom a copy of this Prospectus is delivered, including any beneficial owner, upon the written or oral request of such person, a copy of any or all of the documents incorporated by reference herein (other than exhibits to such documents, unless such exhibits are specifically incorporated by reference into this Prospectus). Requests should be directed to:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CEL-SCI Corporation</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8229 Boone Blvd., Suite 802</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Vienna, Virginia 223l4</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(703) 506-9460</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Attention: Secretary</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">All documents filed with the Commission by CEL-SCI pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of this prospectus and prior to the termination of this offering shall be deemed to be incorporated by reference into this prospectus and to be a part of this prospectus from the date of the filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference shall be deemed to be modified or superseded for the purposes of this prospectus to the extent that a statement contained in this prospectus or in any subsequently filed document which also is or is deemed to be incorporated by reference in this prospectus modifies or supersedes such statement. Such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Investors are entitled to rely upon information in this prospectus or incorporated by reference at the time it is used by CEL-SCI even though that information may be superseded or modified by information subsequently incorporated by reference into this prospectus.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has filed with the Securities and Exchange Commission a Registration Statement under the Securities Act of l933, as amended, with respect to the securities offered by this prospectus. This prospectus does not contain all of the information set forth in the Registration Statement. For further information with respect to CEL-SCI and such securities, reference is made to the Registration Statement and to the exhibits filed with the Registration Statement. Statements contained in this prospectus as to the contents of any contract or other documents are summaries which are not necessarily complete, and in each instance reference is made to the copy of such contract or other document filed as an exhibit to the Registration Statement, each such statement being qualified in all respects by such reference. The Registration Statement and related exhibits may be examined at the Commission&#8217;s internet site (www.sec.gov).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><u>TABLE OF CONTENTS</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">PAGE</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:0in">THE COMPANY</p></td> <td style="width:9%;vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:right;">5</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:0in">FORWARD LOOKING STATEMENTS</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:right;">14</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:0in">RISK FACTORS</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:right;">15</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">DILUTION</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">15</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">USE OF PROCEEDS</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">15</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">MARKET FOR CEL-SCI'S COMMON STOCK</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">16</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">SELLING SHAREHOLDERS</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">17</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">PLAN OF DISTRIBUTION</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">18</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">DESCRIPTION OF SECURITIES</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">19</p></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>THE COMPANY</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><u>OVERVIEW AND PRODUCT CANDIDATES</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI Corporation is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body&#8217;s natural defense system. CEL-SCI is currently focused on the development of the following product candidates and technologies:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">1)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck cancers; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">2)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology, or LEAPS, with several product candidates under development for the potential treatment of rheumatoid arthritis.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in this prospectus as Multikine. Multikine is the trademark that the Company has registered for this investigational therapy, and this proprietary name is subject to FDA review under the Company&#8217;s future anticipated regulatory submission for approval. None of the Company&#8217;s product candidates have been approved for sale, barter or exchange by the Food and Drug Administration (FDA) or any other regulatory agency for any use to treat disease in humans nor has the safety or efficacy of these products been established for any use. There can be no assurance that obtaining marketing approval from the FDA in the United States and by comparable agencies in most foreign countries will be granted.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:center;"><strong><u>MULTIKINE, THE PHASE III CLINICAL TRIAL RESULTS AND PATH FORWARD</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong><u>Immunotherapy is a large, high growth market.</u></strong> Immunotherapies use the patient&#8217;s own immune system to fight disease. These &#8220;targeted therapies&#8221; are at the forefront of modern cancer research. A Bloomberg report from January 2023 asserted that:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The global cancer immunotherapy market is expected to reach USD $196.45 billion by 2030, registering CAGR of 7.2% during the forecast period, according to a new report by Grand View Research, Inc. The rising adoption of immunotherapy over other therapy options for cancer owing to its targeted action is anticipated to increase the adoption during the forecast period. Moreover, increasing regulatory approvals from authoritarian establishments for novel immunotherapy used for oncology is also expected to further fuel the market growth.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><u>Source</u>: <u>https://www.bloomberg.com/press-releases/2023-01-18/cancer-immunotherapy-market-worth-196-45-billion-by-2030-grand-view-research-inc</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI hopes to participate in this growing market with its lead investigational therapy Multikine&#174; (Leukocyte Interleukin, Injection). Multikine is unique among approved cancer immunotherapies because it is <em><u>given first</u></em><u>, right after diagnosis, before any other treatment including surgery.</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Multikine has been tested in approximately 740 patients in Phase 1, 2 and 3 clinical studies conducted in the U.S., Canada, Europe, Israel and Asia. In these studies, it has been administered in multiple doses by various routes and various frequencies to determine its safety and efficacy. The data from these studies allowed CEL-SCI to determine the patient population most responsive to Multikine and most likely to benefit from it. The target population is newly diagnosed advanced primary head and neck cancer patients with no lymph node involvement (determined via PET imaging) and with low PD-L1 tumor expression (determined via biopsy), two features that physicians routinely assess at baseline as part of standard practice.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI completed a bias analysis for the target population in the Phase III study in preparation for submission of data to regulatory agencies including the FDA for confirmatory registration study. The detailed data on parameters including patient age, sex, race, tumor locations, and staging demonstrate balance between the treatment and control arms. Therefore, no bias was found, which supports confidence in Multikine&#8217;s efficacy results.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In the target patient population CEL-SCI believes Multikine significantly extended life. In the Phase III study, CEL-SCI observed a 73% survival rate with Multikine vs. only 45% without Multikine at 5 years after treatment, and a Hazard ratio of 0.35 (95% CIs [0.19, 0.66]).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI applied to the FDA for a 212-patient randomized controlled confirmatory registration study focusing only on those patients in the target population, which accounts for approximately 100,000 patients worldwide per year. In May 2024, CEL-SCI announced that the FDA indicated CEL-SCI may move forward with a confirmatory registration study of Multikine in the target population.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong><u>What is Multikine and who is it for?</u></strong> Multikine is a biological medicinal immunotherapy comprised of a mixture of natural cytokines and small biological molecules. Multikine is injected around the tumor and adjacent lymph nodes for three weeks as a first-line treatment <em><u>before</u></em> the standard of care (SOC), which is surgery followed by either radiotherapy or chemoradiotherapy. Multikine&#8217;s rationale for use is to incite a locoregional immune response against the tumor before the local immune system has been compromised by the standard of care and/or disease progression.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The Multikine target population is not yet treated adult patients with resectable locally advanced primary squamous cell carcinoma of the head and neck (SCCHN) in the oral cavity and who have:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">No lymph node involvement (via PET imaging)</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Low PD-L1 tumor expression (TPS&lt;10) (via biopsy)</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">PD-L1 is a protein receptor on the tumor surface that helps the tumor repel cells of the immune system. CEL-SCI believes that patients with tumors having low PD-L1 would be more likely to respond to Multikine because their tumors have lower defenses against the patient&#8217;s immune system. CEL-SCI estimates that patients with tumors having low PD-L1 represent about 70% of locally advanced primary SCCHN patients.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Targeting low PD-L1 also differentiates Multikine from other immunotherapies. For example, checkpoint inhibitors like Keytruda and Opdivo appear to best serve patients having high PD-L1, because these drugs work by blocking PD1/PD-L1 receptors interaction; when this interaction (PD1/PD-L1) happens it leads to inactivation/death of the immune cells attacking the tumor. These checkpoint inhibitors appear to act best when tumors express high levels of PD-L1 receptors (usually TPS &gt;20 to TPS &gt;50).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Keytruda was approved by FDA in June 2025 as a perioperative (before and after surgery) treatment for resectable locally advanced head and neck cancer patients whose tumors express PD-L1 at a positive level. In Merck&#8217;s Phase 3 KEYNOTE-689 trial, Keytruda reduced the risk of recurrence and progression by 30%, compared with standard of care, in patients whose tumors expressed PD-L1 (CPS &#8805;1). The study did not show an improvement in overall survival. Patients with low to zero levels of PD-L1 did not benefit from Keytruda.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In contrast to the results of the KEYNOTE-689, CEL-SCI&#8217;s Phase 3 study showed that Multikine treated patients whose tumors expressed low (Tumor Proportion Score [TPS &lt;10]) to zero PD-L1, had their risk of death reduced by 66% (hazard ratio 0.34, 95% CI [0.18, 0.65], p=0.0012) and extended the 5-year overall survival to 73% compared to 45% in the standard of care, log rank p=0.0015. About 70% of the patients in CEL-SCI&#8217;s Phase 3 study had low to zero levels of PD-L1.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong><u>CEL-SCI believes Multikine leads to longer survival with no safety issues.</u></strong> Clinical investigations of Multikine, presented at ESMO (Europe Society for Medical Oncology) in October 2023, have demonstrated in the randomized controlled Phase III trial (RCT) the following in the target population:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"><strong><em><u>risk of death cut in half at five years</u></em></strong><strong><em> </em></strong>versus the control;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">28.6% absolute 5-year overall survival benefit versus control (p=0.0015);</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">0.349 hazard ratio vs control (95% CIs [0.18, 0.66], Wald p=0.0012);</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">&gt;35% rate of pre-surgery reductions and/or downstages (p&lt;0.01); and</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">low PD-L1 tumor expression (vs high PD-L1 where Keytruda and Opdivo work best).</td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">There were no demonstrable safety signals or toxicities observed in approximately 740 Multikine-treated subjects across multiple clinical trials. Adverse event (AE) and serious adverse event (SAE) incidences were not significantly different among treatment and control groups. There were no Multikine-related deaths, no Multikine-related delays of surgery, no Multikine-related interference with post-surgical treatment, and only two discontinuations. Multikine-related AEs before surgery were local and resolved after surgery. Although the literature reports that some of Multikine&#8217;s components may be toxic when administered systemically (e.g., TNF&#945;, IFN &#947;, IL-1&#946;), these toxicities did not emerge with Multikine, even at doses many times higher than those administered in the Phase III trial, primarily due to Multikine&#8217;s delivery by local injection and dosage.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI published its data as abstracts and posters at the annual conferences for the 2022 American Society of Clinical Oncology (ASCO), 2022 and 2023 European Society for Medical Oncology (ESMO), the 2023 European Head and Neck Society&#8217;s (EHNS&#8217;s) annual European Conference on Head and Neck Oncology (ECHNO), the 2023 European Society for Therapeutic Radiology and Oncology (ESTRO) and the 2023 American Head and Neck Society (AHNS). These publications can be accessed at <u>http://www.cel-sci.com</u>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong><u>Multikine </u></strong><strong><u>works by inducing pre-surgical responses.</u></strong> CEL-SCI observed statistically significant pre-surgical responses after Multikine treatment, and therefore CEL-SCI believes in the following:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#10146;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Multikine causes pre-surgical responses;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#10146;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pre-surgical responses lead to longer life;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&#10146;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Therefore, selecting more patients predicted to have a pre-surgical response should lead to much better survival in the target population.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">A &#8220;pre-surgical response&#8221; is a significant change in disease before surgery. CEL-SCI saw two kinds of responses in the Phase III trial. First, there were &#8220;reductions&#8221; in the size of the tumor&#8212;a reduction of 30% or more qualified as a &#8220;pre-surgical reduction,&#8221; or &#8220;PSR&#8221; for short. Second, there were disease &#8220;downstages&#8221; (e.g., the disease improved from Stage IV to Stage III) pre-surgery. CEL-SCI calls this a &#8220;pre-surgical downstaging&#8221; or &#8220;PSD&#8221; for short. CEL-SCI&#8217;s 2022 ESMO cancer conference presentation reported on PSR, and CEL-SCI&#8217;s new 2023 ESMO presentation reported on PSD.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Across the whole Phase III trial, PSRs were seen in 8.5% of Multikine patients compared to <em><u>none</u><strong> </strong></em>in the control group. PSDs were seen in 22% of Multikine patients as compared to 13% in the control group. Because Multikine was the only therapy given to these patients before surgery, it is CEL-SCI&#8217;s strong belief that Multikine had to be the cause of the higher rates of PSR and PSD.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">These data are presented visually below. The taller blue columns show PSR and PSD rates in all 529 Multikine-treated patients in the Phase III trial, and the gray columns show PSR and PSD rates for all 394 control patients.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_ex99img15.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">It was not enough for us to show that Multikine likely leads to PSRs and PSDs as compared to a control group, CEL-SCI also had to test if PSRs and PSDs lead to improved survival. CEL-SCI&#8217;s Phase III trial demonstrated that PSR patients were 72% likely to be alive after five years, whereas control patients were only about 49% likely to be alive after five years. Patients with PSD saw similar improvement in CEL-SCI&#8217;s Phase III trial. Their five-year chance of survival was approximately 68%. Therefore, CEL-SCI believes that the Phase III trial demonstrated that those patients who had PSR or PSD resulting from Multikine lived longer than those who were not treated with Multikine. It is important to note that these results are from the entire Phase III study population, not from a subgroup. The likelihood of living at least five years is shown in the graphic below for patients with PSR (blue), patients with PSD (orange) and control patients who did not receive Multikine (gray).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_ex99img16.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong><u>Multikine cut the 5-year risk of death in half in the target population.</u></strong><strong> </strong>CEL-SCI&#8217;s results show that Multikine can cut the risk of death in half at five<strong> </strong>years versus the control group in the target population. Survival increased from 45% in the control group to 73% in the Multikine group at five years. This means the risk of death fell to 27% in the Multikine group from 55% in the control, shown below.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_ex99img10.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Another way to see the survival benefit of Multikine in the target population is the Kaplan-Meier curve from our ESMO &#8217;23 poster, shown below. On the vertical axis is the probability of survival and the horizontal axis is time in months. The blue Multikine line is far above the green control line, meaning the chance of survival is much higher in the Multikine group at every point in time compared to the control. These results had a low (log rank) p-value of 0.0015, which is very significant as a statistical matter.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_ex99img17.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s physician consultants tell CEL-SCI that the early separation of these two survival curves (e.g., at 12 months) adds validation to the potential positive effects of Multikine.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Another measure of survival benefit is called the &#8220;hazard ratio,&#8221; which compares the rate of an event (chances) of dying between two different groups. Here, in the Multikine target population, the hazard ratio was 0.35, which means that deaths occurred in the Multikine group about one-third as frequently as in the control group. It is also important to note that the hazard ratio&#8217;s 95% confidence interval remained far below 1.0 (which would mean parity between the compared groups). In the case of Multikine, statistically speaking, there is a 95% chance that the hazard ratio would fall between 0.18 and 0.66 if Multikine were tested in the target population in another study. A hazard ratio of 0.66 as the &#8220;so called worst case scenario&#8221; (the upper limit of the 95% confidence interval - for the hazard ratio - in this case) is still below (better) than the hazard ratio required for most drug approvals.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI completed a bias analysis for the target population in the Phase III study in preparation for submission of data to regulatory agencies including the FDA for confirmatory registration study. The detailed data on parameters including patient age, sex, race, tumor locations, and staging demonstrate balance between the treatment and control arms. Therefore, no bias was found, which supports confidence in Multikine&#8217;s efficacy results.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_ex99img18.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">These positive survival outcomes&#8212;increased overall survival, reduced risk of death, widely separated Kaplan-Meier curves with early separation, low hazard ratio, low p-values, low confidence intervals&#8212;CEL-SCI believes were driven by high PSR/PSD rates in the target population, as shown in the graphic below:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_ex99img19.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI relies on all of these data together to support its plan to request accelerated/conditional approval in the new target population without waiting until the completion of another clinical trial. CEL-SCI&#8217;s regulatory strategy going forward is to seek approval of Multikine following full enrollment of our confirmatory study wherever possible.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI applied to the FDA for a 212-patient randomized controlled confirmatory registration study focusing only on those patients in the target population, which accounts for approximately 100,000 patients worldwide per year. In May 2024, CEL-SCI announced that the FDA indicated CEL-SCI may move forward with a confirmatory registration study of Multikine in the target population.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">The confirmatory study will be a randomized controlled trial with two arms: Multikine treatment plus standard of care versus standard of care alone.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">If approved as a pre-surgical treatment, CEL-SCI believes Multikine should be added to the standard of care for the target population in this unmet medical need.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">CEL-SCI believes that the confirmatory study has a high likelihood of success based on the large survival benefit that has already been observed in the target population from the completed Phase III study. The planned confirmatory study will be much smaller&#8212;less than a quarter the size of the prior study&#8212; and will focus on the patients who saw the greatest survival benefit when treated with Multikine.</td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Why Do We Believe Our Confirmatory Study Will Be Successful?</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_ex99img20.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">An &#8220;unmet need&#8221; is a factor for approval considered by all major regulatory bodies worldwide. In the Multikine target population, there is also a great unmet need for improved survival. The current standard of care provides only about a 50/50 chance of surviving five years, whereas Multikine could increase that survival rate to over 70% in the target population based on the Phase III data. Chemotherapy (in addition to radiotherapy following surgery) has improved survival outcome for some head and neck patients, but chemotherapy is only indicated for high-risk patients, who are not likely to fall within the Multikine target population. Currently available immunotherapies are given after surgery or where surgery is not indicated, in contrast to Multikine, which is given before surgery to patients with resectable tumors. Available checkpoint inhibitors work best on tumors with high PD-L1 expression, whereas Multikine works best in tumors with low PD-L1 expression. Therefore, Multikine&#8217;s target population is underserved, and will continue to be underserved, by current therapies.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The major regulatory bodies with whom we are working, U.S. FDA, Health Canada, European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) all have conditional approval pathways designed for situations where the target population has not been fully tested prospectively and there is strong data supporting clinical benefit for patients. The reason is that regulators understand that in many cases patients should not have to wait for additional data before being offered the chance to benefit from a new drug, especially if the drug has been shown to be safe. Every situation is different and depends on the specific facts.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>IN CONCLUSION</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"><strong>Strong survival data</strong>: Multikine-treated patients in the target population had a 73% 5-year survival vs a 45% 5-year survival in the control group who did not receive Multikine in the Phase III study. In addition, no safety signals or toxicities versus standard of care. The Hazard ratio is 0.35 with an upper limit (95% Confidence Interval) of 0.66.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"><strong>Addressing an unmet medical need</strong>: Multikine focuses on the 70% of patients (based on CEL-SCI&#8217;s 928 patient Phase III study) not well served by Keytruda.</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"><strong>Multikine&#8217;s Target Population</strong>: The confirmatory registration study will focus on newly diagnosed locally advanced primary head and neck cancer patients with no lymph node involvement (determined via PET scan) and with low PD-L1 tumor expression (determined via biopsy).</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"><strong>FDA pathway</strong>: CEL-SCI&#8217;s goal is to begin the 212-patient confirmatory registration study as soon as the needed capital has been raised, with full enrollment about 15 months later with the potential to seek early approval after full enrollment.</td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>FORWARD LOOKING STATEMENTS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">This prospectus and the documents that are incorporated or deemed to be incorporated by reference into this prospectus, contain or incorporate by reference &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You can generally identify these forward-looking statements by forward-looking words such as &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;future,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;plans,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;potential,&#8221; &#8220;continues&#8221; and similar words or expressions (as well as other words or expressions referencing future events, conditions or circumstances). These forward-looking statements involve risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements, including, but not limited to:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the progress and timing of, and the amount of expenses associated with, our research, development and commercialization activities for our product candidates, including Multikine;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our expectations regarding the timing, costs and outcome of any pending or future litigation matters, lawsuits or arbitration proceeding;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the success of our clinical studies for our product candidates;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our ability to obtain U.S. and foreign regulatory approval for our product candidates and the ability of our product candidates to meet existing or future regulatory standards;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our expectations regarding federal, state and foreign regulatory requirements;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the therapeutic benefits and effectiveness of our product candidates;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the safety profile and related adverse events of our product candidates;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our ability to manufacture sufficient amounts of Multikine or our other product candidates for use in our clinical studies or, if approved, for commercialization activities following such regulatory approvals;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our plans with respect to collaborations and licenses related to the development, manufacture or sale of our product candidates;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our expectations as to future financial performance, expense levels and liquidity sources;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our ability to compete with other companies that are or may be developing or selling products that are competitive with our product candidates;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">anticipated trends and challenges in our potential markets;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our ability to attract, retain and motivate key personnel;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our ability to continue as a going concern; and</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">our liquidity.</td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">All forward-looking statements contained herein are expressly qualified in their entirety by this cautionary statement, the risk factors set forth under the heading &#8220;Risk Factors&#8221; and information elsewhere in this prospectus and in the documents incorporated or deemed to be incorporated by reference into this prospectus. The forward-looking statements contained in this prospectus and any document incorporated or deemed to be incorporated by reference in this prospectus, speak only as of their respective dates.&nbsp;&nbsp;Except to the extent required by applicable laws and regulations, we undertake no obligation to update these forward-looking statements to reflect new information, events or circumstances after the date of this prospectus or to&nbsp;reflect the occurrence of unanticipated events. In light of these risks and uncertainties, the forward-looking events and circumstances described in this prospectus and the documents that are incorporated by reference into this prospectus may not occur and actual results could differ materially from those anticipated or implied in such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>RISK FACTORS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Investing in our securities involves a high degree of risk. In addition to the other information contained in this prospectus and in the documents we incorporate by reference, you should carefully consider the risks discussed below and under the heading &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the fiscal year ended September 30, 2024 before making a decision about investing in our securities. The risks and uncertainties discussed below and in our Annual Report on Form 10-K for the fiscal year ended September 30, 2024 are not the only ones facing us. Additional risks and uncertainties not presently known to us may also harm our business. If any of these risks occur, our business, financial condition and operating results could be harmed, the trading price of our common stock could decline and you could lose part or all of your investment.</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>The exercise of outstanding warrants and options will cause dilution.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">As of August 29, 2025, there were outstanding warrants which allow the holders to purchase 36,418 shares of common stock with a weighted average exercise price of $94.76 per share and outstanding options which allow the holders to purchase up to 710.494 shares of common stock, with a weighted average exercise price of $152.03 per share. The exercise of these outstanding warrants and options will cause dilution to holders of our common stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>A provision in our Bylaws regarding shareholder claims may not be enforceable.</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Article X of our bylaws provides that stockholder claims brought against us, or our officers or directors, including any derivative claim or claim purportedly filed on our behalf, must be brought in the U.S. District Court for the district of Delaware.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The exclusive forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum the stockholder finds favorable for disputes with CEL-SCI or its directors or officers, and may have the effect of discouraging lawsuits with respect to claims that may benefit CEL-SCI or its stockholders.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Although it is our intent that this provision applies to actions arising under the Securities Act of 1933 and the Securities Exchange Act of 1934 there is uncertainty as to whether a court would enforce this provision since Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations under the Securities Act.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In addition, since this provision in our bylaws applies to state law claims there is uncertainty as to whether any court would enforce this provision.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>DILUTION</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">As of June 30, 2025, we had a net book value was approximately $1.30 per share. An investor will suffer dilution equal in amount to the difference between the price paid for the shares and our net tangible book value at the time of purchase.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>USE OF PROCEEDS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">All of the shares offered by this prospectus are being offered by certain owners of CEL-SCI&#8217;s common stock (the Selling Shareholders) and were issued by CEL-SCI in connection with CEL-SCI's employee stock option, bonus and compensation plans. None of the proceeds from this offering will be received by CEL-SCI. Expenses expected to be incurred by CEL-SCI in connection with this offering are estimated to be approximately $10,000. The Selling Shareholders have agreed to pay all commissions and other compensation to any securities broker/dealers through which they sell any of the Shares.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>MARKET FOR CEL-SCI&#8217;S COMMON STOCK</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Our common stock is publicly traded on the NYSE American under the symbol &#8220;CVM&#8221;. The following table sets forth, for the periods indicated, the high and low intraday sale prices of our common stock as reported by the NYSE American.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Quarter Ending</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">High</p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Low</p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>FY 2023</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">12/31/2022</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">110.40</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">56.40</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">3/31/2023</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">99.90</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64.50</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">6/30/2023</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">88.20</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">55.80</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9/30/2023</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">89.70</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">32.40</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>FY 2024</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">12/31/2023</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">96.90</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">31.20</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">3/31/2024</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">92.40</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">48.90</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">6/30/2024</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">71.70</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">33.00</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">9/30/2024</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">66.60</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30.60</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>FY 2025</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">12/31/2024</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">33.90</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11.10</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">03/31/2025</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20.41</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6.65</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">06/30/2025</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.60</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.98</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Through 08/29/25</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.48</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.21</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">As of August 29, 2025, there were&nbsp;7,993,356 outstanding<strong>&nbsp;</strong>shares of our common stock outstanding held by approximately 430 holders of record.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Holders of common stock are entitled to receive dividends as may be declared by the Board of Directors out of legally available funds and, in the event of liquidation, to share pro rata in any distribution of CEL-SCI&#8217;s assets after payment of liabilities. The Board of Directors is not obligated to declare a dividend. CEL-SCI has not paid any dividends on its common stock and CEL-SCI does not have any current plans to pay any common stock dividends.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The provisions in CEL-SCI&#8217;s Articles of Incorporation relating to CEL-SCI&#8217;s preferred stock would allow CEL-SCI&#8217;s directors to issue preferred stock with rights to multiple votes per share and dividend rights which would have priority over any dividends paid with respect to CEL-SCI&#8217;s common stock.&nbsp;&nbsp;The issuance of preferred stock with such rights may make more difficult the removal of management, even if such removal would be considered beneficial to shareholders generally, and will have the effect of limiting shareholder participation in certain transactions such as mergers or tender offers if such transactions are not favored by incumbent management.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The market price of CEL-SCI&#8217;s common stock, as well as the securities of other biopharmaceutical and biotechnology companies, have historically been highly volatile, and the market has from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. Factors such as fluctuations in CEL-SCI&#8217;s operating results, announcements of technological innovations or new therapeutic products by CEL-SCI or its competitors, governmental regulation, developments in patent or other proprietary rights, public concern as to the safety of products developed by CEL-SCI or other biotechnology and pharmaceutical companies, and general market conditions may have a significant effect on the market price of CEL-SCI&#8217;s common stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">16</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SELLING SHAREHOLDERS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has issued (or may in the future issue) shares of its common stock to various persons pursuant to certain employee compensation plans adopted by CEL-SCI. The employee compensation plans provide for the grant or issuance to selected employees of CEL-SCI and other persons of shares of CEL-SCI&#8217;s common stock or options to purchase shares of CEL-SCI&#8217;s common stock. Persons who received shares pursuant to the Plans and who are offering such shares to the public by means of this Prospectus are referred to as the &#8220;Selling Shareholders&#8221;.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Bonus Plans, Stock Compensation Plans and an Incentive Stock Bonus Plan. All Stock Option, Bonus and Compensation Plans have been approved by CEL-SCI&#8217;s stockholders. A summary description of these Plans follows. In some cases, these Plans are collectively referred to as the &#8220;Plans&#8221;.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong><u>Incentive Stock Option Plans</u></strong>. The has Incentive Stock Option Plans authorize the issuance of shares of CEL-SCI&#8217;s Common Stock to persons who exercise options granted pursuant to the Plans. Only CEL-SCI&#8217;s employees may be granted options pursuant to the Incentive Stock Option Plans.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Options may not be exercised until one year following the date of grant. Options granted to an employee then owning more than 10% of the common stock of CEL-SCI may not be exercisable by its terms after five years from the date of grant. Any other option granted pursuant to the Plans may not be exercisable by its terms after ten years from the date of grant.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The option exercise price is determined by CEL-SCI&#8217;s Compensation Committee but cannot be less than the fair market value of the common stock on the date of the grant of the option (or 110% of the fair market value in the case of a person owning more than 10% of CEL-SCI's outstanding shares).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong><u>Non-Qualified Stock Option Plans</u></strong>. The has Non-Qualified Stock Option Plans authorize the issuance of shares of CEL-SCI&#8217;s Common Stock to persons who exercise options granted pursuant to the Plans. CEL-SCI&#8217;s employees, directors, officers, consultants and advisors are eligible to be granted options pursuant to the Plans, provided however that bona fide services must be rendered by such consultants or advisors and such services must not be in connection with a capital-raising transaction or promoting CEL-SCI&#8217;s common stock. The option exercise price is determined by CEL-SCI&#8217;s Compensation Committee.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong><u>Stock Bonus Plans</u></strong>. Under the Stock Bonus Plans shares of CEL-SCI&#8217;s common stock may be issued to CEL-SCI&#8217;s employees, directors, officers, consultants and advisors provided however that bona fide services must be rendered by consultants or advisors and such services must not be in connection with a capital-raising transaction or promoting CEL-SCI&#8217;s common stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong><u>Stock Compensation Plans</u></strong>. Under the Stock Compensation Plans shares of CEL-SCI&#8217;s common stock may be issued to CEL-SCI&#8217;s employees, directors, officers, consultants and advisors in payment of salaries, fees or other compensation owed to these persons. However, bona fide services must be rendered by consultants or advisors and such services must not be in connection with a capital-raising transaction or promoting CEL-SCI&#8217;s common stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong><u>Incentive Stock Bonus Plan.</u> </strong>Under the 2014 Incentive Stock Bonus Plan shares of CEL-SCI&#8217;s common stock may be issued to executive officers and other employees who contribute significantly to the success of CEL-SCI. The purpose of the Plan is to provide long term incentive for outstanding service to CEL-SCI and its shareholders, to assist in recruiting and retaining people of outstanding ability and initiative in executive and management positions to allow officers and employees to participate in CEL-SCI's future prosperity and growth, and to align the interests of CEL-SCI&#8217;s officers and employees with those of its shareholders.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">17</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><u><strong>Summary</strong></u>.&nbsp;The following lists, as of August 29, 2025,&nbsp;the options and shares available pursuant to the Plans. &nbsp;Each option represents the right to purchase one share of CEL-SCI's common stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Name of Plan</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total Options Reserved Under Plans</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Option Plans</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,613</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Non-Qualified Stock Option Plans</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">709,573</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Bonus Plans</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">59,460</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Compensation Plans</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21,134</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Bonus Plan</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21,334</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Shares issuable upon the exercise of options granted to CEL-SCI&#8217;s officers and directors pursuant to its stock option plans are being offered by means of this Prospectus. The following table lists the shareholdings of CEL-SCI&#8217;s officers and directors and the shares offered by means of this prospectus as of August 29, 2025.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:6%;"></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="10"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Number of Shares Being Offered</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:6%;"></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:6%;"></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Name of Selling </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shareholder</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Number of Shares Owned</p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Option Shares <sup style="vertical-align:super">(2)</sup></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Bonus Shares <sup style="vertical-align:super">(1)</sup></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Stock Bonus Shares</p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Number of shares which will be owned on completion of the Offering</p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Percent of Class</p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Geert R. Kersten</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">72,835</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><sup style="vertical-align:super">(3)</sup></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">25,000</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,933</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">70,902</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">*</td> <td style="width:1%;white-space: nowrap;"></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Patricia B. Prichep</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">10,747</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">12,000</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,033</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9,714</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">*</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Eyal Talor, Ph.D.</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5,548</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">15,000</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,033</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">4,515</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">*</p></td> <td style="width:1%;white-space: nowrap;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">John Cipriano</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2,104</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7,500</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">533</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,571</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">*</p></td> <td style="width:1%;white-space: nowrap;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Bruno Baillavoine</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">199</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">199</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">*</p></td> <td style="width:1%;white-space: nowrap;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Robert Watson</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">3,733</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">3,733</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">*</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">*</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Less than 1%.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(1)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Includes shares awarded pursuant to CEL-SCI&#8217;s 2014 Incentive Stock Bonus Plan that have not vested.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(2)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Represents shares issued or issuable upon exercise of stock options. The options held by CEL-SCI&#8217;s officers and directors are exercisable at prices of between $8.20 and $618.30 per share.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(3)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Includes shares held in trusts for the benefit of Mr. Kersten&#8217;s children, and shares held in the de Clara Trust, for which Mr. Kersten is a beneficiary.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Mr. Kersten is an officer and director of CEL-SCI. Mr. Baillavoine and&nbsp;Mr. Watson are directors of CEL-SCI. The other persons in the foregoing table are officers of CEL-SCI.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has filed with the Commission under the Securities Act of 1933 a Form S-8 registration statement of which this prospectus forms a part with respect to the resale of the shares from time to time in the public market or in privately negotiated transactions.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PLAN OF DISTRIBUTION</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The Selling Shareholders may sell the Shares offered by this Prospectus from time to time in negotiated transactions in the public market at fixed prices which may be changed from time to time, at market prices prevailing at the time of sale, at prices related to such prevailing market prices or at negotiated prices. The Selling Shareholders may effect such transactions by selling the Shares to or through broker/dealers, and such broker/dealers may receive compensation in the form of discounts, concessions, or commissions from the Selling Shareholders and/or the purchasers of the Shares for which such broker/dealers may act as agent or to whom they may sell, as principal, or both (which compensation as to a particular broker/dealer may be in excess of customary compensation).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">18</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The Selling Shareholders and any broker/dealers who act in connection with the sale of the Shares hereunder may be deemed to be &#8220;underwriters&#8221; within the meaning of Section 2(11) of the Securities Act of 1933, and any commissions received by them and profit on any resale of the Shares as principal might be deemed to be underwriting discounts and commissions under the Securities Act. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has advised the Selling Shareholders that they and any securities broker/dealers or others who may be deemed to be statutory underwriters will be subject to the prospectus delivery requirements under the Securities Act of 1933. CEL-SCI has also advised each Selling Shareholder that in the event of a &#8220;distribution&#8221; of the shares owned by the Selling Shareholder, such Selling Shareholder, any &#8220;affiliated purchasers&#8221;, and any broker/ dealer or other person who participates in such distribution may be subject to Rule 102 under the Securities Exchange Act of 1934 (&#8220;1934 Act&#8221;) until their participation in that distribution is completed. A &#8220;distribution&#8221; is defined in Rule 102 as an offering of securities &#8220;that is distinguished from ordinary trading transactions by the magnitude of the offering and the presence of special selling efforts and selling methods". CEL-SCI has also advised the Selling Shareholders that Rule 101 under the 1934 Act prohibits any &#8220;stabilizing bid&#8221; or &#8220;stabilizing purchase&#8221; for the purpose of pegging, fixing or stabilizing the price of the common stock in connection with the sale of the Shares by any Selling Shareholder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>DESCRIPTION OF SECURITIES</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Common Stock</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI is authorized to issue 600,000,000 shares of common stock, (the "common stock"). Holders of common stock are each entitled to cast one vote for each share held of record on all matters presented to shareholders. Cumulative voting is not allowed; hence, the holders of a majority of the outstanding shares of common stock can elect all directors.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Holders of common stock are entitled to receive such dividends as may be declared by the Board of Directors out of funds legally available therefor and, in the event of liquidation, to share pro rata in any distribution of CEL-SCI's assets after payment of liabilities. The board is not obligated to declare a dividend. It is not anticipated that dividends will be paid in the foreseeable future.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Holders of common stock do not have preemptive rights to subscribe to additional shares if issued by CEL-SCI. There are no conversion, redemption, sinking fund or similar provisions regarding the common stock. All of the outstanding shares of common stock are fully paid and non-assessable.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Preferred Stock</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI is authorized to issue up to 200,000 shares of preferred stock.&nbsp;CEL-SCI's Articles of Incorporation provide that the Board of Directors has the authority to divide the preferred stock into series and, within the limitations provided by Colorado statute, to fix by resolution the voting power, designations, preferences, and relative participation, special rights, and the qualifications, limitations or restrictions of the shares of any series so established.&nbsp;As the Board of Directors has authority to establish the terms of, and to issue, the preferred stock without shareholder approval, the preferred stock could be issued to defend against any attempted takeover of CEL-SCI.&nbsp; As of the date of this prospectus no shares of preferred stock were outstanding.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">19</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Rights Agreement</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In October 2020, CEL-SCI declared a dividend of one Series A Right and one Series B Right, or collectively the Rights, for each share of CEL-SCI&#8217;s common stock which was outstanding on October 30, 2025.&nbsp;&nbsp;When the Rights become exercisable, each Series A Right will entitle the registered holder, subject to the terms of a Rights Agreement, to purchase from CEL-SCI one share of CEL-SCI&#8217;s common stock at a price equal to 20% of the market price of CEL-SCI&#8217;s common stock on the distribution date, although the price may be adjusted pursuant to the terms of the Rights Agreement.&nbsp;&nbsp;If after a person or group of affiliated persons has acquired 15% or more of CEL-SCI&#8217;s common stock or following the commencement of a tender offer for 15% or more of CEL-SCI&#8217;s outstanding common stock (i) CEL-SCI is acquired in a merger or other business combination and CEL-SCI is not the surviving corporation, (ii) any person consolidates or merges with CEL-SCI and all or part of CEL-SCI&#8217;s common shares are converted or exchanged for securities, cash or property of any other person, or (iii) 50% or more of CEL-SCI&#8217;s consolidated assets or earning power are sold, proper provision will be made so that each holder of a Series B Right will thereafter have the right to receive, upon payment of the exercise price of $100 (subject to adjustment), that number of shares of common stock of the acquiring company which at the time of such transaction has a market value that is twice the exercise price of the Series B Right.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The description and terms of the Rights are set forth in a Rights Agreement between the Company and Computershare Trust Company, N.A., as Rights Agent.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><u>Distribution of Rights</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Initially, stockholders will not receive separate certificates for the Rights as the Rights will be represented by outstanding common stock certificates. Until the exercise date, the Rights cannot be bought, sold or otherwise traded separately from the common stock. Certificates for common stock will carry a notation that indicates that Rights are attached to the common stock and incorporate the terms of the Rights Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Separate certificates representing the Rights will be distributed as soon as practicable after the earliest to occur of:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">15 business days following a public announcement that a person or group of affiliated or associated persons has acquired beneficial ownership of 15% or more of CEL-SCI&#8217;s outstanding common stock, or</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">15 business days (or such later date as may be determined by action of CEL-SCI&#8217;s board of directors prior to such time as any person or group of affiliated persons has acquired 15% or more of CEL-SCI&#8217;s common stock) following the commencement of, or announcement of an intention to make, a tender offer or exchange offer the consummation of which would result in the beneficial ownership by a person or group of 15% or more of such outstanding common stock.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The earlier of such dates described above is called the &#8220;distribution date.&#8221;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Until the distribution date (or earlier redemption or expiration of the Rights), the surrender for transfer of any certificates for common stock outstanding as of the record date, even without such notation, will also constitute the transfer of the Rights associated with the common stock represented by such certificate. As soon as practicable following the distribution date, separate certificates evidencing the Rights will be mailed to holders of record of the common stock as of the close of business on the distribution date, and such separate right certificates alone will evidence the Rights.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;<u>Exercise and Expiration</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The holders of the Rights are not required to take any action until the Rights become exercisable. The Rights are not exercisable until the distribution date.&nbsp;&nbsp;Holders of the Rights will be notified by CEL-SCI that the Rights have become exercisable.&nbsp;&nbsp;The Rights will expire on October 30, 2025, unless the expiration date is extended or unless the Rights are earlier redeemed by CEL-SCI as described below.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">20</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><u>Redemption</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">At any time prior to the distribution date, CEL-SCI&#8217;s board of directors may redeem the Rights in whole, but not in part, at a price of $0.0001 per Right. Subject to the foregoing, the redemption of the Rights may be made effective at such time, on such basis and with such conditions as CEL-SCI&#8217;s board of directors in its sole discretion may establish. Immediately upon any redemption of the Rights, the right to exercise the Rights will terminate and the only entitlement of the holders of Rights will be to receive the redemption price.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><u>Exchange Option</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">At any time after a person or group of affiliated persons has acquired 15% or more of CEL-SCI&#8217;s common stock or following the commencement of a tender offer for 15% or more of CEL-SCI&#8217;s outstanding common stock, and prior to the acquisition by such person of 50% or more of the outstanding common stock, CEL-SCI&#8217;s board of directors may exchange the Rights (other than Rights owned by such person or group which have become void), in whole or in part, at an exchange ratio of one share of common stock per Right (subject to adjustment).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Transfer Agent</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Computershare Trust Company, Inc., of Denver, Colorado, is the transfer agent for CEL-SCI's common stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">21</td></tr></table></p> <p style="margin:0px"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>8
<FILENAME>cvm_ex107.htm
<DESCRIPTION>FILING FEE
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ffd="http://xbrl.sec.gov/ffd/2024q2" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><head><title>cvm_ex107.htm</title><!--Document Created by XBRLMaster--><meta http-equiv="Content-Type" content="text/html"/></head><body style="text-align:justify;font:10pt times new roman"><div style="display:none;text-align:justify;font:10pt times new roman;" id="XBRLDIV"><ix:header><ix:hidden><ix:nonNumeric name="ffd:FeeExhibitTp" contextRef="From2025-08-22to2025-08-22" id="ixv-638">EX-FILING FEES</ix:nonNumeric><ix:nonNumeric name="ffd:SubmissnTp" contextRef="From2025-08-22to2025-08-22" id="ixv-639">S-8</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="From2025-08-22to2025-08-22" id="ixv-640">0000725363</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ffd/2024q2/ffd-2024q2.xsd"/></ix:references><ix:resources><xbrli:context id="From2025-08-22to2025-08-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-22</xbrli:startDate><xbrli:endDate>2025-08-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Scties424iAxis_From2025-08-22to2025-08-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="ffd:Scties424iAxis"><dei:lineNo>1</dei:lineNo></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-22</xbrli:startDate><xbrli:endDate>2025-08-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="OfferingAxis_From2025-08-22to2025-08-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="ffd:OfferingAxis"><dei:lineNo>1</dei:lineNo></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-22</xbrli:startDate><xbrli:endDate>2025-08-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:right;"><strong>EXHIBIT 107</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Calculation of Filing Fee Tables</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><span style="text-decoration:underline"><ix:nonNumeric id="fid_4138e7ac" contextRef="From2025-08-22to2025-08-22" name="ffd:FormTp">S-8</ix:nonNumeric></span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(Form Type)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><span style="text-decoration:underline"><ix:nonNumeric contextRef="From2025-08-22to2025-08-22" name="dei:EntityRegistrantName" id="ixv-675">CEL-SCI Corporation</ix:nonNumeric></span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(Exact Name of Registrant as Specified in its Charter)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><span style="text-decoration:underline">Table 1: Newly Registered and Carry Forward Securities</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Security Type</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Security Class Title</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Fee </strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Calculation or Carry Forward Rule</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Amount Registered</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Proposed Maximum Offering Price Per Unit</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Maximum</strong> <strong>Aggregate Offering Price </strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Fee Rate</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Amount of Registration Fee</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Carry Forward Form Type</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Carry Forward File Number</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Carry Forward Initial effective date</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward</strong></p></td><td>&#160;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:15%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><ix:nonNumeric id="fid_49f539db" contextRef="Scties424iAxis_From2025-08-22to2025-08-22" name="ffd:PrevslyPdFlg" format="ixt:fixed-true">Fees to be Paid</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><ix:nonNumeric id="fid_035dd25f" contextRef="OfferingAxis_From2025-08-22to2025-08-22" name="ffd:OfferingSctyTp">Equity</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><ix:nonNumeric id="fid_cf6847f3" contextRef="Scties424iAxis_From2025-08-22to2025-08-22" name="ffd:OfferingSctyTitl">Common Stock, Preferred Stock, Rights and Warrants</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><ix:nonNumeric id="fid_889bc4b0" contextRef="OfferingAxis_From2025-08-22to2025-08-22" name="ffd:Rule457oFlg" format="ixt:fixed-true">Rule 457(o)</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_51112b40" contextRef="OfferingAxis_From2025-08-22to2025-08-22" name="ffd:AmtSctiesRegd" format="ixt:num-dot-decimal" decimals="0" unitRef="USD">133,334</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_6855bb21" contextRef="OfferingAxis_From2025-08-22to2025-08-22" name="ffd:MaxOfferingPricPerScty" format="ixt:num-dot-decimal" decimals="INF" unitRef="USD">13.04</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:5%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_0b5d7c57" contextRef="OfferingAxis_From2025-08-22to2025-08-22" name="ffd:MaxAggtOfferingPric" format="ixt:num-dot-decimal" decimals="INF" unitRef="USD">1,738,675</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">$<ix:nonFraction id="fid_411f2a2b" contextRef="Scties424iAxis_From2025-08-22to2025-08-22" name="ffd:FeeRate" decimals="INF" unitRef="Pure" scale="-2">153.10</ix:nonFraction> per 1,000,000</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_79d20ccb" contextRef="Scties424iAxis_From2025-08-22to2025-08-22" name="ffd:FeeAmt" format="ixt:num-dot-decimal" decimals="INF" unitRef="USD">266.19</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Fees Previously Paid</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Carry Forward Securities</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Total Offering Amounts</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_08160b3f" contextRef="From2025-08-22to2025-08-22" name="ffd:TtlOfferingAmt" format="ixt:num-dot-decimal" decimals="INF" unitRef="USD">1,738,675</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_cc560f25" contextRef="From2025-08-22to2025-08-22" name="ffd:TtlFeeAmt" format="ixt:num-dot-decimal" decimals="INF" unitRef="USD">266.19</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Total Fees Previously Paid</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">--</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Total Fee Offsets</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">--</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Net Fee Due</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><strong><ix:nonFraction id="fid_8dd90725" contextRef="From2025-08-22to2025-08-22" name="ffd:NetFeeAmt" format="ixt:num-dot-decimal" decimals="0" unitRef="USD">266</ix:nonFraction>.19</strong></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td>&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span style="text-decoration:underline">Table 2 &#8211; Fee offset claims and sources</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric id="fid_c7fc5739" contextRef="From2025-08-22to2025-08-22" name="ffd:OffsetTableNa">N/A</ix:nonNumeric></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span style="text-decoration:underline">Table 3 &#8211; Combined prospectuses</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric id="fid_759948be" contextRef="From2025-08-22to2025-08-22" name="ffd:CombinedProspectusTableNa">N/A</ix:nonNumeric></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>cvm_ex99img20.jpg
<TEXT>
begin 644 cvm_ex99img20.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" $& C$# 2(  A$! Q$!_\0
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M !\2?]]FJ_LVB^_WA]<J^1]J_P#"TM$_Z!NJ?]^5_P#BJ/\ A:6B?] W4_\
MORO_ ,57Q2+N<]+J0_\  S5FS34=0NC;6DDDDHC>7;YF/E1"['D]E4G\*?\
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MY'VK_P +2T'_ *!NJ?\ @.O_ ,51_P +2T'_ *!NJ?\ @.O_ ,57Q5]IN?\
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MW/\ S\2_]]FC^RJ?G]X?7*GD?:O_  M+0?\ H&ZI_P" Z_\ Q5'_  M+0?\
MH&ZI_P" Z_\ Q5?%7VFY_P"?B7_OLT?:;G_GXE_[[-']E4_/[P^N5/(^U?\
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MJ 1N)!R>@7&,FKB^$]/TZUUT:M=39CTN"^LI?LC*X#SHF60L"K?>0@YZD@G
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC%K.K_#D"/MJBBBOF#K/$?CUFV^*GPVU2XU#7-(L;:+4A/J>B6S33V^Z.,*
M C_>/!XZ$U@>+-)T#QYHWPS:"Z\2>*8+7Q8NGW=YJT,]M<&&12[A@JQX4?(
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MDW:S0&:-OF(V< 9SG'(&35^Y^'ES;?:+%UU!=0MX&F>=K=19LZIO:,/G=TR
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MG,ZW'D(\&(86DR0[;]S!<G;N [XKDO\ A"_%O_0KZM_X R__ !-'_"%^+?\
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M/5_^@[J?_@+:_P#QNCZA6[K\?\A?6J?9GU3\M'RU\K?\+RUC_H.ZG_X"VO\
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M / 6U_\ C='U"MW7X_Y!]:I]F?5/RT<?Y%?*W_"\M8_Z#NI_^ MK_P#&Z/\
MA>6L?]!W4_\ P%M?_C=5_9];NOQ_R#ZY3[,^J?EH^6OE;_A>6L?]!W4__ 6U
M_P#C='_"\M8_Z#NI_P#@+:__ !NC^SZW=?C_ )!]<I]F?55%?*O_  O/5_\
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M_P#OE?\ "BN;V,BO;P-VBBBN<[ HHHH **** "BBB@ K(M_^1OO_ /KSM_\
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M@?\ )-O$G_8-N/\ T6:*7QQ]13^%GPM<?\?,GUIL<<DTT<,2EI)&"*HZL2<
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M=CG<GEOO7;Z<UT2Z#HC^&KB\DUBWM8X=7:U^W212%GC\D,%6(98X.23VQUY
MJ"7P?-9'46U;5(+*"QO/L33I#).C/MWACL'RH5((8]<\ X-7[2#W#EDMCF1)
M()O.$CB7.[S QW9]<]:0DDEB223DD]2:&&UF4,& )&Y>A]Q25V$!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !6]X+_P"2@>'?^PE;_P#HQ:P:WO!?_)0/#O\ V$K?_P!&+6=7
M^'($?;5%%%?,'6=!1117F'MA1110 4444 %%%% !61;_ /(WW_\ UYV__H<U
M:]9%O_R-]_\ ]>=O_P"AS4UU)?0U>]<O\0/^2;>)/^P;<?\ HLUU'>N7^('_
M "3;Q)_V#;C_ -%FBE\<?44_A9\,3NZW$NUV4-\K;3C</0^HIUA=?8=4L[[9
MYGV:>.;9G&[:P;&??%1W'_'S)]:2"&2YN8K:%=TLSK&@SC+$X _,U]C ^<.F
MT'QG<Z%XJO-86S2YM;V=YYK*1OE+%F9&!QPZ%N&QZCH345GXBT](M*FU/13?
M7^D(L=M(MQY<<JHQ:,3)M);:3_"5R, ^M8]UI>H6.M2Z/=6DB:C%/]F:WQEO
M,SC:,=<G&,=<TS4-/NM+U:ZTO4(O)O+20Q31[@VUAP1D<&HY*;?J7S21<T[7
M)K/6;S59X_M4]W#<QR$G;EID96;\"Y.*MZ9XMU2RO= DNY6O;30F8VMLQVA0
MV<C.,]^^<  #BLF+3KJ;3&U&)%:W6X2TW;AGS'!*C'T4\U9M]!U*YU5]*C6%
M;Y+Q;$P/,H;S2Q7 YY *D$C@<>M:25-WO_7]7$G+H:VE>*K'3VT"\N=#-YJ.
MAA8X)#<[(I$$C.N]-N2P+, 0P'3(..2P\5VMG_8S2:3)+)IGVF'(N=HE@F\S
M<N-O#CS#ANG XKF[>W>YN?LZR11OM9LRR!%^4$GD]^,#U.!WJ#<N0-PR>U1[
M*#'SR1U5IXO;3+)+72;2:U$-I>6D,OVC,D8G=&W;@HY79CC&<]L4)XO(:2XE
MTY7O;@6OVJ<28\]X)A()",<,P4*Q[GYNI-<KN7=MW#/I2]!75[*'87/(Z"U\
M47-C=ZQ>6D(CN-0NHKN-]V?(>.X\X<8^;GCM5C5_%C:C;7"P?VI#+<R"1Q-J
M<DL4/.XK&G'&?[Q;  QZURVY0,E@!TZU:2QN9-)FU154VL,R0.V[D.ZLRC'T
M1N:APA>X<TMC0M_$6H+]O-_<7.HM=V,EDK7%PSF(.RG<-V?[O2M*P\8R6^D6
M%A>+J+C3@R0?8]0>V21"Q?9(H!R S'YE*G!QG@$<O;127EW#:VP$DTTBQ(H(
MY9C@#\2123(UO-)#-A'B=HW!/1@<$?F*EPB]&@4I+4ZNQ\81V]M9K=:?/-=6
MZW4)N8[HHYCG)9BI*DK*K'A\GC((YS4B^,[=1IMNVF7,]I907EJWG7Q>::.X
M7:QWE<*PY(P,=L=SQI90,E@![U;O;&YT^2!+I0K3P1W*8;.8W7<I_+M2=*%Q
M\\CI;?QEY5A9V<D.IB+3PT=JEMJ;P*\18LL<H5?FP6/S+M)!QV!JK'XDLIX-
M/?6M)DU"^TTG[/.MT8Q(OF&0),,$L S-@@@D'!/>N9#*20&!(]*M6EE<7T-[
M+;!62RA^T398#:FY5S[\LO%+V<$'/)FFGB*6#QK/XFM[6/,US+,UM*2R,LNX
M/&2,'!5V&1@U?M?%5EHUKY/AO2);.47MO?)/<W7GLKQ%L)@*H*8<CU]ZY3(X
MYZT@922 P)%)THO<2DT=BWC7R[RWNK6VOY3'=)<M!?ZE)<0@*=WEJN!\N<<M
MN(P,=,E8_&D=K';QVEE>SB#5(-4#ZA?M.[/'N^3[H !#=1SGDYZ#C=RXSN&/
MK064 $L #WS6OL8=A\\C:U/5K.ZT:72=/L);6V:^:]4S3^:X+1A"I(5<],]/
M;WK8A\96R>)+C7FL+Z"ZEE23%GJ!B61515\N0%"&7Y<]OO$5QU(&4YPP./>K
M]G%JPN9HFN)OM%W/<>6D7G2-)Y<8PB9).%'8#.!45&>:0,I&0P(^M:$BT5/8
MVEQJ6H0:?8Q^=<SN(XXPP&YCT&3Q5;>F =PP>G/6CF =15FUL;F\BO);=5*6
M<!N9B6QM0,JY'KRR\55#*1N# CUH 6BK.G65QJVHP:?8JLD\[;4!8*O )))/
M   ))/0 U'=1+:W3P?:K>X"]);>0/&_NK=Z7-K8/,BHHR,XSS2!E)(# D=J8
M"T4A95^\P'UI<CGGI0 44F1G&1F@,IZ,#]#0 M%(&4D@,"11N4G 8$T +11D
M<\]*,C.,\T %%)N48RP&>G/6ER,XSS0 44@922 P)'I5M[&Y32X=490+6:9[
M=&W<ET5688^CKS1<"K12!E;[K _2@,ISA@<=>>E "T59T^QN-5N_LMBJR2^7
M))@L -J(7;G_ '5-5=PV[B<#U-%^@"T4FY<9W#'K1N7;NW#'KGB@!:*LS6-S
M;V%E?2JH@OE=H6# E@C;&R.W(JM1>X!1110 5O>"_P#DH'AW_L)6_P#Z,6L&
MM[P7_P E \._]A*W_P#1BUG5_AR!'VU1117S!UG04445YA[84444 %%%% !1
M110 5D6__(WW_P#UYV__ *'-6O61;_\ (WW_ /UYV_\ Z'-374E]#5[UR_Q
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MWV;UWMO//9AZ5V?]CZ&-$_LW[1;&W6;^UO-ROF'2-V\1YZ^9OXQU_"O*@,
M=!1@>GO6LJ5TK/82G:^AZAIMPVH:+9ZEI%O=B\O+J>34H]/M+>14<R92.42$
M;8A'MQT3[V3FJ5Y?:+%9:';Q6L-CHE]JUTMYA4DE6U$\?[OS!D[0-Q&T\CN:
M\\QU]QBBH]BK[_U_P ]H>D>)_P!WH^KIJ-E?/!Y@6P>6&VA@A??E3;LARZ%
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M,I(.>0>"/8UE>^[_ *U+^1Z-)!K,NC^(SXQTN"UM8&MA%(EM'&88S=1AQ 4
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MX%%%% !1110 4444 %%%% %,+!"QG6%%>3[S*H!;ZGO5K (.>0>QHHH S_\
M1O\ GB/^^12_Z/\ \\A_WR***VNSBLA/]'_YXC_OD4O[C_GD/^^1111<D/W'
M_/(?]\BC]Q_SS'_?(HHHNPL@_<?\\A_WR*/W'_/(?]\BBBBX@_<?\\A_WR*/
MW'_/(?\ ?(HHHNP#]Q_SR'_?(H_<?\\Q_P!\BBBBX[(/W'_/,?\ ?(H_<?\
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EBBB['9"?Z/\ \\A_WR*7;;_\\5_[Y%%%*X6+&Q?2BBBD58__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>cvm_ex99img19.jpg
<TEXT>
begin 644 cvm_ex99img19.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" 'O @L# 2(  A$! Q$!_\0
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MI(Y'?O77ZE\8+ZZ\;ZCX-^'_ ()D\5ZAI4,<M]))J45A''YBAE5"X)<X(S@
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M%A\Z:^TRR6:"W7=C$CEUVG_$4 >$ZY\)]0U;PY\:[V\\"_:]=O\ 6#-H=Q)
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MW!LC<1V\UQ$H9;8.VT229((0,0"1G&<G@$CI: "BBB@ HHHH **** "BBB@
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M^W6?_/<?D: +=%5/MUG_ ,]Q^1H^W6?_ #W'Y&@"W153[=9_\]Q^1H^W6?\
MSW'Y&@"W153[=9_\]Q^1H^W6?_/<?D: +=%5/MUG_P ]Q^1H^W6?_/<?D: +
M=%5/MUG_ ,]Q^1H^W6?_ #W'Y&@"W153[=9_\]Q^1H^W6?\ SW'Y&@"W153[
M=9_\]Q^1H^W6?_/<?D: +=%5/MUG_P ]Q^1H^W6?_/<?D: +=%5/MUG_ ,]Q
M^1H^W6?_ #W'Y&@"W153[=9_\]Q^1H^W6?\ SW'Y&@"W1WJI]NL_^>X_(U4O
M-8M+.U,[,TOS*NR,99BS!1C..Y%"5]$!K5Y/\1/B9K'AGQ'_ &'X=TJPO9;;
M0KO7KZ6^N'B2"&$@*/E4\LVX<XZ5WW_"0)_T#;S\D_\ BJ\VU3X>^%_$7Q"U
M/Q=XHTNZUM;NUMK6WLIXU6.V2(LQ!Q)^\#,V2&&..]5RLGF1UFG^,OM'PHL?
M'EYI%[$L^FQZA)8VL1GG7<@;:J@ L>?;CTK$^'OQ$UCXBWSZII]AI6G^'4C(
M\I[X3ZB9,_+YD2?+ .N58EOI79IK$,<:QQZ7=HBC"JJQ@ >@^:LI;/PVOB0>
M)$\*[-:\MH3?)#$LS(<95F#98<#KFBS#F1X_\3?B%XYL?%WC[^P/%5OHEGX(
MT^SO8K&2TCE&J--\S!V?Y@HX4;".2*[/XG?$;4/#_P '+CQ!H=U:VNM[+(.)
M<2?8/M#H/,=/0!CC=P2.]:_B+PKX#\5ZO:ZUXD\#1ZGJ-I@1SSPH6P#D _/A
M@#V;(JS>:+X1O;K6[JZ\(FXEUV*.'4C*B,+I(QM0,"^/E'3%'*PYD>.:I\2O
MB!X7L_&_A5_%D6LWVDZGI-C:^(9K.)/(2\&7+HGR$ICC/KSZ5:F\9?%:WT+Q
MIX=T[5)O$VH^'=;M+1]9M-/A>Z%E-'OE9(!B-Y4. ![\]*]'L_"/P]T3P=J/
MANU\!QP:%=YFO+7R499L<[F)<DD8&.>,<5?7X<_#6/P9+X/A\,V$>@SRBXDL
MT#*LD@((9B#N)X'4]L4FFAIW,'X$^-O$7C/P_P"(?^$AGGO3I.K26-O>7-JE
MM-,@56Q+'&2@==V#MXKV*N9T72_#?AG2(='T&QM=-LH!^[M[>/8@SU. .2>Y
MZFMO[=9_\]Q^1I#+=%5/MUG_ ,]Q^1H^W6?_ #W'Y&@"W153[=9_\]Q^1H^W
M6?\ SW'Y&@"W153[=9_\]Q^1H^W6?_/<?D: +=%5/MUG_P ]Q^1J>*>*8$Q.
M& ]* )**** "BBB@ HHHH **** "BBB@ HHHH **** "BBJ4D[R,8K;#$<,Y
M^ZG^)]J 'S3+$ N"[M]U%ZG_ #ZTR.%G<37!#..54?=3Z>I]ZFAMTA!(RSG[
MSMR6J>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHI,X&3TH 2FM7A'Q,^.EEH@FT7PA(E[J8RLEWPT,'KM_OM^
M@]^E>*?\+>^(_P#T-5U_WRO^%>G0RRM7CS:+U."IC:=.7+N?<E9VI1R36:+&
MNYA<0M@>@E4D_D":^+/^%O?$C_H:KK\E_P */^%O?$C_ *&JZ_)?\*Z5D]9?
M:7X_Y&3S"F^C/N3FCFOAO_A;WQ(_Z&JZ_)?\*/\ A;WQ(_Z&JZ_)?\*/['K?
MS+\?\@_M"GV9]Q]N:3MSTKX</Q>^(P&3XLNP/HO^%=)\-_BEXXUKXG:%I-_X
MBN+BRN+C9+&X7#C:>.E<]3+:M.+DVM"X8R$I**3/L.BBBO+/1*&L?\@&_P#^
MO>3_ -!-6XO]2O\ NBJFL?\ (!O_ /KWD_\ 035J#_4I_NBGT)ZDM%%%(H**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BL[4+Z/3K&6\DBFE2,#Y((S(
M[$G  4<DY-8MGXMLKH:@LUK>V%Q80?:IK:[AV2>5@X8#)# [6'!ZB@#JZ*YC
M2_%D.J1B;^Q=5LK0P_:!=7<*I$4QG.0Q/3GI4&G^--'U"&[NBMU9QVMN+PF[
MA,9D@.=LJ>JG:??VYH ZZBJ=M<+<VD-P(WB$JAMDBX9<C.".QJY0 4QW6-"[
ML%4=2:CFG6' P6=ONHO4U%' TCB6XPS#E4'W5_Q/O0 G[ZZ_O1P?DS_X#]:M
M(BQH$10JCH!VI]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!AZMJVGZ'ILVHZI>1VEM$-S22' 'M[GV')K
MY>^)7QHU;Q09=(\.^?I^DC*O)]V:Y'^T1]U?]D=>_I7N'QL_Y)C=_P#7:+_T
M*OE2OI\ERZG7C[:>Z=CPL?BYTY^SCM8YG9)_<;\J-C_W&_*NFHK[/ZMYGB>V
M\CF=C_W&_*C8_P#<;\JZ:BCZMYA[;R.9V/\ W&_*F2,(ES("/08ZUU-8/B+[
MUM]&_I656C[.#E<NG4YI6L8TDS2'T'I7;_!S_DL/AG_KZ_\ 937"5WOP<_Y+
M-X9_Z^O_ &4UXN(=Z4_1_D>A2^./JC[VHHHKX0^E,_6/^0#?_P#7O)_Z":MP
M?ZE/]T54UC_D W__ %[R?^@FK<'^I3_=%-;$]26BBBD4%%%% !1110 4444
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M<JCTV$F@":BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HZ"J\LJ0KND;
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M=3IKVMQ)'!;MYAWN0N5/.<AL=*Z*[U75?#_Q'^(3KH=YXMM[J**UN&TX^48
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MS>U=710!Q'A7P_JFDWSWVK26GF+8V^G1I9;@K)%NP[;@,,=W0< #J:[>BB@
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M8HJO]CA]9/\ OXW^-'V.'UD_[^-_C0!8HJO]CA]9/^_C?XT?8X?63_OXW^-
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M_P#]>\G_ *":MP?ZE/\ =%-;$]26BBBD4%%%% !1110 4444 %%%% !1110
M4444 %%9VH7UKI>F7&H7TGE6]NADD?&< >PZ_2L2S\96=[)#$VGW]E)+>&Q"
MW404I+Y0E 8 G&5/'OP<4 :VL:/I^O:5+I>K6_VBSFQYD19EW8((Y4@]0*IV
MOA/1;6&XACM[B6*YC,,L=Q>33JR'J,.Y _"NBHH YW2_"^B:+=/<:=9E+AD$
M?FR2O*X0'.T,[$A<]A@5<;3[%K^XOGMU>:6$6[NW.8P2=N#QC).?7OTK6HH
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M(D2%Y&"J.YH ?5(S23,8[8\#AI3T'T]3^E&V6ZYD!CA_N?Q-]?3Z5;50JA5
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M'^I3_=%5-8_Y -__ ->\G_H)JW!_J4_W136Q/4EHHHI%!1110 4444 %%%%
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MMB__ +]O_P!\M_C1B_\ []O_ -\M_C5FB@"MB_\ []O_ -\M_C1B_P#[]O\
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M,7WDKAX/NC^%O\:36/\ D W_ /U[R?\ H)JU#_J4_P!T570G[1'B_P#[]O\
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M55HXFG28J/,0%5;N <9_D/RJQNI]A)CJ*;YB_P!ZC>OK19CNA]%%%(9FS?\
M(Q6O_7M-_P"A1UHUG3?\C%:_]>TW_H4=:-#Z$KJ+11104%%%% !1110 4444
M %%%% 'EOQT_Y)7>?]=X?_0J^2*^MOCK_P DIO?^NT/_ *%7R37V^0_P7ZO\
MD?.9A_%^04445]&>8%%%% !6)KOWK?Z-_2MNL37?O6_T;^E<N(_ALTI?&C&K
MO?@U_P EI\,?]??_ +*:X&N]^#/_ "6KPO\ ]??_ +*U>!7_ (<O1GIT_C7J
M?H#1117QQ[Y$Z+(ACD4,C#!4C((J3H/:EHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** ,3Q)J#:7X9U'41:_:S;P,_D=I..A]!Z^V:X_2-)NO"VOV$M
MSH?AV%-4D-MY^E0/')"Y1G ^8G<AV$'&WL<>G3^+IK6W\&ZM->68O;9;=O,M
MRQ42#I@D<@>OM7GT>@^$Y/%"6<?AFT?2EO1IB7"WDQE^T>3YI*C=C8!\O7.?
M:@#UBZ6Z:TE%D\27.T^6TRED#=L@$$CZ$5Q_A>]UW4/ &I37-W]KUA)KZ%)(
MUV@NDCJ@4=@,# -=4MFUKI?V'2V6U,47E0&13(L>!A<C(+ ?7\:P/#_A[6M$
MTC4-/DUZ*;[1)+-#-#9^6T$DCL[-AG8,,MP,=N] &'X9O+F$_9[B^\0_\)%]
MA:5+'5V BG<*-Q3 P0&([Y /2LW2/$FL1V-PD.J7E]-<VL$>^_BV?9M0?=YJ
MC*K\B("[+R%"]>:[2Q\.ZE_PD%MK6N:RFHW%I$\-LD-MY"1[\;W(W,68[0.H
M ':K-_H,6JZJ]Q?3%X!9R6D4(7'EF3B1\^I7 'H,^M #/#NO:7K%L+?3;Z:[
M>VBCW//$\;R*1\LOS ;@V"0PX/-=-7)^'/#-SH]X]Y?:M]ON!:0V,3+ (0L,
M98KD9.6)8Y/ ] *ZR@"FS37#&./,48X:0CD_[O\ C5B.*.% D:[1_.I** "B
MBB@ HHHH 91_#3&940NQP ,YKY=^)GQCUC7#-HOA..:RTTY22\^[+<#T'=%_
M4^W2NK"X.KBY<M-;;OL<]?$0H1O)G=_$KXV:?X7\[1O#K1ZAJXRKR?>BMC[_
M -YO8<#OZ5\R7WBCQ%J5_->WVM7<UQ,VYW,I&3]!P/H*S_L5W_SP:C[%=_\
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M0![A\"M2OM0\5:K]JN9)56T^568D#YUKZ#KYR_9\_P"1HU;_ *\__9UKZ-H
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MH \X\3_\C'<_1?\ T$5BDUL>)S_Q45Q]%_\ 016(6H ]J_9[/_%5:M_UY_\
MLZU]'U\W?L\G/BK5_P#KS_\ 9UKZ1H **** "BBB@ HHHH **** "BBB@ HH
MHH J7EK;7EE-:WD:RV\J%)$?HRGJ#7EMG#Y7P-\3V>E($$4FHI'%#_"@F?@
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M;^5? 6>:^HR'XI_(\/,OL_/]!^:-U1[J-U?9W/#)-U&ZH]U&ZBX$F:I:J?\
MB53?0?SJSNJGJA_XE<WT'\ZSJ/W'Z%P^)',4@[4F:3/S"OG:K/21^D7A/_D2
M]#_Z\(/_ $6M;7:L7PG_ ,B7H?\ UX0?^BUK:[5\5+XF?00V1GS_ /(PVO\
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M/:DAM]K^9,WF2_WNR^P':@!/+DN3NF^6+M%Z_P"]_A5SH*** "BBB@"I>?\
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M?^6BU].^5>?\_2?]^O\ Z] %FBJWE7G_ #])_P!^O_KT>5>?\_2?]^O_ *]
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M;PJ"!UQ0!L02/)$&>/83VJ6BB@ HHHH ***0D*,G@4 >4_'W_DD-[_U\0_\
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M5'0")J )(X%CRW+NWWG;J?\ ZWM5FJGVM?\ GE/_ -^FH^UK_P \I_\ OTU
M%NJ=_P#;/L[+9J#)CC)I?M:_\\I_^_34?:U_YY3_ /?IJ /%/%?P_P#B!XBN
M'/VJ!8FSA3)7G_\ PSIXS_Y^K/\ [Z_^O7U7]J7_ )Y3_P#?IJ/M:_\ /*?_
M +]-730Q57#W]G*US&I1IU;<ZO8^5/\ AG/QG_S]6?\ WU_]>C_AG/QG_P _
M5G_WU_\ 7KZK^TK_ ,\9_P#OVU'VI?\ GE/_ -^VKI_M/$?S?@9?4Z/\I\J?
M\,Y^,_\ GZL_^^O_ *]'_#.?C/\ Y^K/_OK_ .O7U7]J7_GE/_W[:D^U+_SR
MF_[]-1_:>(_F_ /J='^4^5?^&<_&?_/S9_\ ?7_UZBN?V;?&5Q;O#]LLUW=\
MY_K7U?\ :E_YYS_]^FI/M2?\\9_^_34GF6(:LY?@"PE):\I\>G]E7Q@3DZG:
MD_Y]Z3_AE3Q?_P!!*U_S^-?8OVM?^>4__?IJ/M:_\\I_^_35Y[=]6=>Q\:M^
MR=XM9]W]HVO^?QI?^&3_ !:.FI6H'M_^NOLG[6O_ #RG_P"_34?:U_YY3_\
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MX4   9[<DDFNDHHH **** "BBO(TU_4)/$5U%8^(KRXU=-::V&E>6KP_91*
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M>1^<=,XP/PJQK&MZE#K7]BZ+I\=Y=K;_ &J=Y[CR4BC)*K@A6)8D-@8 XY-
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M*FUT9%6((N[ #$YD.0  *ZS2?#=GI,]I-;S3NUK8+IZ;R"#&K9!.!]ZNDHH
M\\U3PO>:9#ID?ARWU.:6"U:S:>VO(82T><JLGF*>,DG<@W#G'6K:^"/.\+Z?
MH=YK-Z+6*QCL[JV@*>5.%7!/S(67//*D'I7<44 11QK'&L:#"J H'H!4M%%
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MU=&61%=#E6&0?45)5>R_X\;?_KFO\JL4 %%%% !1110 4444 %%%% !1110
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MO4<GBN@HH 8JJBA5&% P .U/HHH **** "BBB@ HHHH **** "BBB@ HHHH
6**** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>cvm_ex99img18.jpg
<TEXT>
begin 644 cvm_ex99img18.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" &W <\# 2(  A$! Q$!_\0
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M "[2VX.2^[(8 5S&@^,/&FI>'+NXT/Q3X@UG5&\-:S-J$<BLR6<\<F+1HCM
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MO_R+1]O^('_0KZ'_ .#J7_Y%H ZFBN6^W_$#_H5]#_\ !U+_ /(M'V_X@?\
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M2_\ R+1]O^('_0KZ'_X.I?\ Y%H ZFBN6^W_ ! _Z%?0_P#P=2__ "+1]O\
MB!_T*^A_^#J7_P"1: .IHKEOM_Q _P"A7T/_ ,'4O_R+1]O^('_0KZ'_ .#J
M7_Y%H ZFBN6^W_$#_H5]#_\ !U+_ /(M'V_X@?\ 0KZ'_P"#J7_Y%H ZFBN6
M^W_$#_H5]#_\'4O_ ,BT?;_B!_T*^A_^#J7_ .1: .IHKEOM_P 0/^A7T/\
M\'4O_P BT?;_ (@?]"OH?_@ZE_\ D6@#J:*Y;[?\0/\ H5]#_P#!U+_\BT?;
M_B!_T*^A_P#@ZE_^1: .IHKEOM_Q _Z%?0__  =2_P#R+1]O^('_ $*^A_\
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MU]: /1**Y'R?B7_T$?#/_@%<?_':/)^)?_01\,_^ 5Q_\=H ZZBN1\GXE_\
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M/OB;_O[;_P#QFC_A#+[_ *'WQ-_W]M__ (S0!UM%<E_PAE]_T/OB;_O[;_\
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M$Q()&6VA0<XR#@9!!P*[.N2_X0R^_P"A]\3?]_;?_P",T?\ "&7W_0^^)O\
MO[;_ /QF@#K:*Y+_ (0R^_Z'WQ-_W]M__C-'_"&7W_0^^)O^_MO_ /&: /'_
M (E>!=9\=_'*?3=-CM(%_P"$>@VZI=K+NL&^U.?,MRO'G8[$CC':J\GBSXF1
M^+O&,#ZM<1/80ZHL-@UL[L88H<VLT>(MH);!W%SOW$ 9&*]H_P"$,OO^A]\3
M?]_;?_XS1_PAM]_T/GB;_O[;_P#QF@#RG3]<\66OB_0=/U[Q5X@@CDL=.N+$
M0Z>LHU.>9F-TDVV/"J@V#JNQ3GDBN87QM\5#X<\87$NL746JV]NY>P6T=Y+*
M;[:L:>7^Y"!?*)^7<^X8;UKWW_A#+[_H??$W_?VW_P#C-'_"&7W_ $/OB;_O
M[;__ !F@#Q:67Q<WCG07U;7O$!LM&\7:AIR78A^_"UDKP&54CPZF5B@.,8)'
M!Y':?!?Q#XBU>#7;+Q%J%YJL]G+$1J#QE+>8LI)$:M&CH1@;HV!VD@ UVO\
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M#@  ?*:))H88C-+*D<8Y+LP _.@">BFA@20#DCK[4Z@ HHHH **** "BBB@
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M>OO715S=CXP\,ZI"\VG:Y;7$:3QV[-&V0'<X0?1CP#T/8UTE !1110 4444
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M_P")A<<_^1* .QHKCO\ A6W@PDC^SK@XZ_\ $PN./_(E+_PK;P;_ - VX_\
M!A<?_'* .PHKC_\ A6W@W_H&W'_@PN/_ (Y1_P *V\&_] VX_P#!A<?_ !R@
M#L**X_\ X5MX-_Z!MQ_X,+C_ ..4?\*V\&_] VX_\&%Q_P#'* .PHKC_ /A6
MW@W_ *!MQ_X,+C_XY1_PK;P;_P! VX_\&%Q_\<H ["BN/_X5MX-_Z!MQ_P"#
M"X_^.4?\*V\&_P#0-N/_  87'_QR@#L**X__ (5MX-_Z!MQ_X,+C_P".4?\
M"MO!O_0-N/\ P87'_P <H ["BN/_ .%;>#?^@;<?^#"X_P#CE'_"MO!O_0-N
M/_!A<?\ QR@#5US38=6T>2SD,RD,LT;0.$D21&#(5)X!# =>*X3PGX/\2>'?
M$>G,LC_8#"&NB+G,:_NF7R=G5BK>5A_1#TS@ZNH>"/ >EV,M]?6TUO;1#+R/
MJ%S@<X'_ "TY.>U/M? _P_O'$=G"\[-"EP FHW!_=OG:W^LZ'!Q0!RE]\*;B
M^T76[MEQJMQ<W,L5J)@()BTQ:&9^/]8L;, >V[V&(-:\#^,-6UC7)_[,M+<W
M5GJ=N)(WC1)_-">1G'SL?EY+]#T&*ZR#P?\ #FZUR\T2W1Y-1LHXY;BV74;G
M?$KYV$CS.^#4\G@/P.ES!;M8W'FSAC&!>W)#;>O._ Z]Z ,/0_!^N0?$B3Q!
MJ5K.%>[GO%N5GAVK')$%6!@ 9'VGC&=OR@@]J]9KCA\-_!9&X:?.1Z_VA<?_
M !RE_P"%;>#?^@;<?^#"X_\ CE '845Q_P#PK;P;_P! VX_\&%Q_\<H_X5MX
M-_Z!MQ_X,+C_ ..4 =A17'_\*V\&_P#0-N/_  87'_QRC_A6W@W_ *!MQ_X,
M+C_XY0!V%%<?_P *V\&_] VX_P#!A<?_ !RC_A6W@W_H&W'_ (,+C_XY0!V%
M%<?_ ,*V\&_] VX_\&%Q_P#'*/\ A6W@W_H&W'_@PN/_ (Y0!V%%<?\ \*V\
M&_\ 0-N/_!A<?_'*/^%;>#?^@;<?^#"X_P#CE '845Q__"MO!O\ T#;C_P &
M%Q_\<H_X5MX-_P"@;<?^#"X_^.4 =A17'_\ "MO!O_0-N/\ P87'_P <H_X5
MMX-_Z!MQ_P"#"X_^.4 3>+-+U#7;>PT6!0--N;E6U*0M@^0GS>6!U.]@JG_9
M+5Q=GX3\6:1XUFN=/CN#:OJT^I-<_P!H#[/-;R(3]G\@]'WD -C@#.[M77?\
M*V\&_P#0-N/_  87'_QRL74/#7PQTO5;/2]0E^RWEYCR89-2N SY.!_RTXR>
M!GJ>!S0!LR:?JVM>*M%U#5+-;33M.MOM0MQ,)"UZXVX.."(UW8/<OD=*[&N/
M_P"%;>#?^@;<?^#"X_\ CE'_  K;P;_T#;C_ ,&%Q_\ '* .PHKC_P#A6W@W
M_H&W'_@PN/\ XY1_PK;P;_T#;C_P87'_ ,<H ["BN/\ ^%;>#?\ H&W'_@PN
M/_CE'_"MO!O_ $#;C_P87'_QR@#L*XKQ]H^IZWX7BM-+A,TD=Y!<2)',(9FC
M1PQ\J0\))P"&R.AY&:E_X5MX-_Z!MQ_X,+C_ ..4?\*V\&_] VX_\&%Q_P#'
M* /,;WX>>,9M+2'^S)9!);7D,$<>I*DL+2S^8OVQ\XN$/!8#=T(P<YKLO%6D
M^)-0-GJ%KHMQ_:-D)K1+BPU&.!I(W1/F(=2HC9AR/O+M!&:@T_2/A3JFKC1]
M/G,]^0[" 7]T&(7[Q&7YQD5HS>#?AW#K-MH\T;)J-W&\L-L=2N/,D1,;F \S
MH-PY]Z .@\(Z-)X=\%Z/H4\PFFL;2.!W!)#,J@'&>V:Z*N/_ .%;>#?^@;<?
M^#"X_P#CE'_"MO!O_0-N/_!A<?\ QR@#L**X_P#X5MX-_P"@;<?^#"X_^.5J
M:+X;TGP\9ETFWDA$Y!DWW$DN<9Q]]CCJ>E &Y1110 4444 %<WXRT^\U;P'K
MVEZ?%YMW=V,T,*;@NYV0@#)X')[UTE% 'B\OA'Q5IKWL+6,OB&"]73O-NKIH
MGF1(PX>((&C5@K;6&<#YV)W8Q2>&/"OB#3[S2&\1^';O4YHX+>*TF%X@&F&.
M60ON._NI0_*&W ;3TKVFB@#RGX?>&=?T;Q%=W>M1WBSF&:.>=FC\B[=I]ZR#
M#EF.WH6"[02N#V]6HHH **** "BBB@ HHHH **** "BBB@ HHHH P=>TO^UM
M'>U:2:*1'2XBDAV[TDC8.A&[Y2=RC@\5PG@_PWXI\.^)=/4_:#I\D"M=$RHT
M2*(F41'^(NK"( @8P&Z9Q7HNL:K;:+IKWURLKJ'2-(X5W/([,%55'<DD"JNC
M^(=-UMLZ=(\J^1%<%RI 42#*J?\ :QR1VR/6@#S*'PAXV76+KQ%=*LC:PU_;
MWME;,L-S!!*N(<3ERI*^5&!@?*7/7!J&S\-^-+738Q8Z#F.UBU!(89Y$@:X$
MD$*QF5$D*ABRR#Y6 .-WR[J[)?B7H;:A<VLEEJ,"1-=I'<20CR[AK8$S*A#$
MY 4D9 SBNAM/$>BWEQ9V\>I6ZW=W"MQ%:O(HE*,NX?+G/3G\#0!Y+:^ =>OF
M>&^T>6/3!-?RP6TDJ1!/,M+=(OW:2,%_>K*0,G!Y[YKU_P .P7EKX7TFWU+=
M]MBM(DGW-N/F! &R>_.>:HR>,?#OG6RVVIPWWGWBV&;619!'*RLPWX/ PC<T
MZY\5:';3LHNA-&NGR:FTT.'C6!"!NR#WYQCKM/I0!TM%<//\0O#]KX,TSQ9*
M;I=/U&6.&-3#^]1F8J=Z_P .S#%O0*?2NXH **** "BBB@ HHHH **** "BB
MB@ HHHH *\B\9>&]>U+7]9M]/TM[N#7K:QMTO%D15LC#.7<N&(;&T[EV@Y(Q
MQUKT;6-2ATC2;C4[I96AMUW,L,;2.W8!57DDD@8JAI/BC3]6TV_OO)NK3^SG
M:.[AN82DL#*@<@J,Y^5@1C.0: .FHKF=!\6:?X@FN(+>WOK.YMECD>"]MS"Y
MCD!*. >QVM[C!R!734 %%%% !1110 4444 </'::PGB77?%=UI<ES+!$+'2K
M))4W/",-(X).U3(^.I'$:YKG(?"?C*/XO:?XDO(=*N[0R72RW*.XE@MR@$,(
M4\<8/3@DL3U%=QK_ (@M?#]O!)=1W%Q)<S+;V]M;1^9+-(03M5?H"23@  U:
MT75['7M(MM8TV0R6MTNY"RE6'.""#R"""".Q!H V:*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,?5M.M=8TR:
MQNX?-1\,J^8T9#J<J0R\J00#D<BN+\._#W4/#_B;3KZ&ZM_LL46ZX*2.&9S&
MR-&JXQY>2C DY'EJ,=ZZWQ%K']BZ,]\L/VB0RQP1QM((U+NX1=S'[HRPR?2L
M_P .^--,\23"*UVHYMHI]CRKO+,NYD"]3M!7)Z9;% '"0_"O6AXAO;L?V7:"
M>YOY6OH9Y9)[B*X5P(7C*A% +*202?D&*O?\*]\67FH:6VHW]E';V;PMFWF;
M,:K9M RJOEC<V]BP=FZ'&!CG4M?B9;S:GH%C-I;VYU%[N*Z<R@BQDA<H%;CG
M>RMCIP*7P]\3M,UB]AL]0LY],GN/LWDY5I$8SQ[XPSA=JDC& 3R30!C7OPUU
MS6_!FG^&;Z32]+2R:VC%YIS/YT\<4;IN8E1U+#Y.1@M\W-7+KP+X@U;1]0M=
M0O;"QN=2:SM)CIY94M[*'!98<KPS,7P", -U.*T['XEZ%=-(MRMQ"L%C!?-<
M)"[PR"5RB(C8RS%@ !C))XZ&K-[X^TBWM;+4+<M-!<23B;(*-;)!&[S,ZD9!
M79C'JP]: .6;X3ZI=ZE<:??>)KG_ (1Y&NY[9HI!]K:6Y0+(),ILV#,N,<_/
MVQ7H7AVSU*P\/Z=8ZO/'<W]O;I#--$25D91C=R ><9/N:PM+\5:U-%#J&M>&
MWL-,N;0WD5Q!-]H>(<$1RH%!#D'("[AD$5IP>./#=Q"95O7C94N&>.2%E>/R
M,>:&4C(*[AQWSQF@#J:*Y2W\9>'[K4UT^WNII9&17\Q;:0Q*6B\T(7V[0QCP
MVTG."/457/Q"\,B LUQ<B;SUMQ:FTE$[,T9D&(]NX@HK-G'0'OQ0!V=%<BWC
M#3X/[1FF$LD5G.L.+:&29SF(2Y90N5PISZ8]^*CM_B#X5N=5M]-@U!Y)KAH4
MC=8)#$6EB$L0+[=H+(<@9H [*BBB@ HHHH **** "BBB@#&UA=6DTRX&AS6\
M.H8!A-RI:(D$$JV.0",C(Z9SSTKE?#/ASQ-H-GJ,%G_9>GQW]S-<B!)9+A;)
MFB 4JS*ID)D&Y@=H .!4WBSQY_PC.IM80Z6;Z2"Q?4[DFX2$);HVT[-WWWZ_
M+QTZC(J/1?B)9^(/%(TW3+2*:S:1HEN/MD:S$J@8OY!.[8"=N[KGMCF@"3PG
MH.LZ7XAUG6M6CL+5M36'S+:QFDF229-V^<M(H*E@R@(. %'))KO:XK6O%&M:
M/XDT[3SX;6YM-0O$M()TO5$ARI9G\O;G"@,3ST%=K0 4444 %%%% !117+>*
M/$2^'=,M[A;=KFYN[J.RMXC((E:1SQN<\*O!YY]!R: (_%NBZIJ+Z-J&C_9G
MOM)O/M4<-T[)'*#&\;*656*G#Y!P>14G@W0Y_#OA&RTFZF2>YC,DLTD8(0R2
M2-(VW/. 7('L*YN?XFW">'Y]:MO#,EQ;Z=YXU-A=QA+9H7VM&C=)7/50,9&.
MA.*UO%GC2W\+MIUJMO'/=WZR2HMU=):1I&@!8L[\ Y90!ZGL!0!V]%9MC=->
M6%M=M"T!FC63RV8,4R,X)4D'Z@D5I4 %%%% !1110 4444 %<A-\1O ]O/)!
M-XFLDEC8HZE^5(.".E=?6/KVK1Z'X;U+6I(VECL+>2X:-3@N%4G /X4 8_\
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M/B;0]0:W6SU".1[F:2WCC(*L9$7<ZD$9!"\G/MZUT- ''_\ "R_ /_0U6/\
MWW_]:C_A9?@'_H:K'_OO_P"M7844 <?_ ,++\ _]#58_]]__ %J/^%E^ ?\
MH:K'_OO_ .M7844 <?\ \++\ _\ 0U6/_??_ -:C_A9?@'_H:K'_ +[_ /K5
MV%% ''_\++\ _P#0U6/_ 'W_ /6H_P"%E^ ?^AJL?^^__K5V%% ''_\ "R_
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M&QUS4_'EG?7-G8?9(EVB-%D8@RS #HS[5&.P! ZFNA_X67X!_P"AJL?^^_\
MZU)K'BK4-'UZQT^;PW<RVU[=QV<%W'<1'<S#);9G=A0&)XZ UV- ''_\++\
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M6L:+XTTK2GL++^S]1NDM8 9V^T2Y7<\H&-BJG3:3DX..PKOJ "BBB@ HHHH
M*YWQ%X=M_$VGPV-U>7EFL-Q'=*]I($;>ARN<@@C.#@CJ!Z5T5<KXPUJ\\.^'
M6U&QM5N)S/# JNDCJN^0*6(C!8@9SP": .$/P;GBTXVT.N17MS-:7&GW-UJE
MF)W\F69Y0T6&78ZEVY.02<XX%=1K'A?Q!?Z2=-BUFPGL_FA-IJ%AY\4L!50O
MF?."TBLI.X$ YY'>L?5_'VL6'A*T\2V<>DWEH@;[3(9)H_,G#[1;QH5W(YP<
MF0 *>H[CH_%^J:SHN@2ZSIS:>MO:0O-<_;FDS@#(";,Y)/'UQB@#;T'3#H_A
M_3]):[EO#9VZ0&>;[\FT8W'ZUKUE:-/J-UH5A<ZM:I::A+ CW$$;%EB<C)4$
M]<'BM6@ HHHH **** "BBB@ KDY/&FEPS/"VGZ\61BI*:'>,I(]"(L$>XKK*
MYSQEJ%UI/@77=2L9!'=VEC--"Q4-M=4)!P>O- $/_"=Z/_T#?$/_ ((;W_XU
M1_PG>C_] WQ#_P""&]_^-5Y8/&WCV&V^R6D\LNI+?V#06^J6D<4]S;R1NTJ_
M)\NUF0JC#D'(-:</Q \47VL7UTJFQTV>]TE;"UN+?9,EO/,\<AD!Y#/MR ?N
MC'K0!Z!_PG>C_P#0-\0_^"&]_P#C5'_"=Z/_ - WQ#_X(;W_ .-5U-% '+?\
M)WH__0-\0_\ @AO?_C5'_"=Z/_T#?$/_ ((;W_XU74T4 <M_PG>C_P#0-\0_
M^"&]_P#C5'_"=Z/_ - WQ#_X(;W_ .-5U-% '+?\)WH__0-\0_\ @AO?_C5'
M_"=Z/_T#?$/_ ((;W_XU74T4 <M_PG>C_P#0-\0_^"&]_P#C5'_"=Z/_ - W
MQ#_X(;W_ .-5U-% '+?\)WH__0-\0_\ @AO?_C5'_"=Z/_T#?$/_ ((;W_XU
M74T4 <M_PG>C_P#0-\0_^"&]_P#C5'_"=Z/_ - WQ#_X(;W_ .-5U-% '(3>
M--)EMWC73_$*[U*Y&@WA(SWYBQ^=<O8?\(GINM66H6UKXJ4V<8"PG0[LI)($
M9/-;]SDOMD?/."6SC-=/\0]3U?1_AYJNH:#<1VVJ1K&MM+,F]$=I%4%AW'S<
MUPEQ\3O$%GXAGU#4M*DL]'M=*E4V$D6V6:^CN((G8-@GR@TNT$9# %AGB@"]
M=V/@F\&FF;3_ !5YNFZH^K02+HMX&\QW+O&?W/,9)Y7V'.1FJO\ 9'@_[++:
MLWC)HA ;>S!T6Z_T"/S5EQ'_ */S\ZKR^[A0.E:=]\4+C3_#KZG<:+&D]L;A
MIK=YW5IHH0I+P@Q[F4ANK!0",$UJ6OCJZN/%JZ6VBK'I[ZE-IBW0N,N94A\W
M=Y>WA2,CKG- %2_U#PSJ>IIJ%]8^)II!I\VG.IT*["R12[=Y(\GK\HZ<<GBL
M.WT_POIIG?31XK#26^QHYM!N&$TH@$(D=_L^_P"Z%R P7(!Q7L]% 'A^E:3H
M]OI-A_:5UXMGUBTM[2*"]70[G-H8%.U8Q]GP5R[YWABP//05HP6'@J+3=0L7
ML_%DJZC8M8W,CZ+>;Y SO(TF1!PY:1CZ=.*]?HH \A-OX9?5[C49X_%<YO$"
MWD;:!< 7;"+RM[,+<,"4 R%*J2!Q5KP[-X?\.WDEXDGC#497M8;)3=Z'=$1P
MQ;MB@+ O/S').2>]>J44 <M_PG>C_P#0-\0_^"&]_P#C5'_"=Z/_ - WQ#_X
M(;W_ .-5U-% '+?\)WH__0-\0_\ @AO?_C5'_"=Z/_T#?$/_ ((;W_XU74T4
M <M_PG>C_P#0-\0_^"&]_P#C5'_"=Z/_ - WQ#_X(;W_ .-5U-% '+?\)WH_
M_0-\0_\ @AO?_C5'_"=Z/_T#?$/_ ((;W_XU74T4 <M_PG>C_P#0-\0_^"&]
M_P#C5'_"=Z/_ - WQ#_X(;W_ .-5U-% 'EWB34-)\1 JUQXRL8I8'M+B*UT6
MZV7$+_>5@\# 'MN7# $\U4\KPX-0@F\_QF+*UF-U:V!T6Z:*VF\LQAT)@+X
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MH=]?27EWIZR7+O!(TA9@2T+%HCP?X2Q/X\UO44 %%%% !1110 4444 %%%%
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MF6-8HO*:1'?$";23AV!08SU:JWA'QI<:EHQC\076F6NNRWUU:PVT4V8V:-R
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M7;.?6N=TGQYK>F^#-+N;I6\0W\FB_P!OW\LS);"* !=R1A5PS9W8!QTY/(H
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M.><YJ*Y\!^%[NS@L9M)Q;P)-$JQ3R1Y29MTJ,58%E9N2IR*\S2XUI?#OBWQ
M\UY&T6J3P1:@=4D8*@O%39Y/W4 7(SZ?6M:^^)6NZ>U]?>39WL ;4HXK"-&$
MT'V4$J[MN.0V.>!C<N#Z@'H]GH.EZ<;TV5OY(O=K7"B1BLA5!&#@G .U5!(Q
MG SFJ%UX&\,WEA86-QI8^SV$'V6"..:1 (>/W3;6&]/E&5;(..E<G9^,_%$W
MBJT\,K>:7<2->I')J$4#&.2-K5IRJJ'^^-N,Y(PRG'K/JGC36K3QE=6-O)91
MVMK?V>G_ &22,FXN//4$S*=PX7=P,'(1LD=@#?U;P/HNI:5>V-O:BRFN#<R+
M<1Y8Q2SQF.20*3@Y5B,=/I63I_PQTU+5[?6F-]&')@@@EFABM5,?ENJ?O"V'
M'+*6VGTKDFF\53?!OP]);^)Y4US4M<CQJ R-Q:X;","3E#M"E1QMXQ4D?BCQ
ME9>*M5OM68:=<:A;Z='!IUS()8-*66Y>$R-M(#$X+$YYRHS@4 >DVOA'P_9Z
MK;7MK8- ]LD:1JD\@C.Q-B%DW;695X#$$X[\5U%>,3?$S5K&TU<73Z>SZ?87
MDL=Q@I'=2PW/DAE!;H1C(!/S9P:C36?&%UXCBLT\21+,?%4]I&&@^6* 6+R!
M&4,-XS@C)'(S0![717-^#=:F\1>"-)UJ[2-+B[MUDD6+.P-T.,]LBNDH ***
M* "BBB@ HHHH **** .9UKP;X?U[5K75=2MKAKVTC:*":"]GMVC5OO >6Z]<
M"FMX'\--JYU;[ QNRQ8G[1+LWE/+,FS=M\S9QOQN]ZZ1W6.-I)#A5!)/M7@]
MCJNLQZ!-H<WB&)]5O[:UNEU5=<>2!U:X",N[9^X9LD#:"#TZB@#UZTT'2]/O
M([RUM-EQ':QV*2M(SL(4)*IEB>YR3U/?.*WJXSP)J0U+P]*C1RK+87DUE*SW
M;70D=&P625@"ZG/!(!'([5V= !1110 4444 %8VK:/INO6'V'5+<S0AUE7:[
M1M&ZG*NK*0RL#T((-;-<GXRUZ?0?#;75K;RRW4\J6T+);R3K"S_\M'5 6V*,
MD\<X [T 5Y?ASX/FM(K>32V5$5T8K=3*TZNVYUE8/F4,W)#ELU/?>"?#.H?\
M?5A)O\UYA)#=31.I90K!61@54JH!0$+QTKQFX^(FJ1_"73(8?$&K^=$TDUUK
M;V,Q>X"7I18@PCPI8#YNF%&!R>.]^*'C-[#PK-9Z)J%S:37,$S2:C;6TDQLE
MC0,5.U3LE;<H ?& 2>U 'I5G9VNGV,%C8P);VMN@CBB085% P *N5A^'+T:A
MX6TJ^61W%Q:12;W4JS90')! (_$5N4 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 0O&LB-'(H9&&&5AD$>E55T^P6
M[CNEL8%N8H_)CF$2[T3^Z#C('MTK*\6VE]?>&)X+%\2!HWD0SF#S8E<&1/,'
MW-R@C/;-<)X)\4:U_P )%I^EZT?M#WMK%%$[3'?L6%W$P0CE7V-ECSED'M0!
MZ>UA9?99K5K* V\^XRQ&-=DA;[VX8P<]\]:AATG2K>\EO(=+MHKF9!'),L*A
MY$' 4L!DC@<&O+-&N=!FOI=0U_7+RV\7C79K=8(KA_."B5EBA$/(\DQ;23MQ
M@EL]ZQ=)\:>+-%\(VL;:C%J'VC3(+J*22(!K3?>K S%F;#@(^<L0,KSQF@#V
MRUT?2=/BBBL=+M+1(G:2-8(%0(Q&"P '!(X)J232]-DU*/4I-/MY+Z)=D=RT
M*F5%] V,@<FO(KSX@>+X8["WCNM.20PW,XO'E@\F[,<XC2-F+[0=I^81ECGI
M6OX#\2:G>>--=T6^F^S6\-W=RVR3?.][^^(8QL>B1<*5Z_,#P,9 /2?L%FL$
M4"VD(BB8/&@C&U&!R"!V.>],FTW3[H3"ZL8)Q.@CE$L2MYB9SM;(Y&2>#7B,
M_B+5K&WT/55\40Z5<7&F:S?2&[ D2:5;B(K'M9@.!\O'. <<FNC/Q&U9;F.U
MD^RQZC)JEO"--(_?>2^GBX*XSG_694-CMCK0!Z/)X=T&:&UAET6PDBM 1;HU
MLA6$'J$&/E_"GKINGC4FOEL;87)8,THB7>6"[0=V,Y"DCZ'%>6VGCC5I/#NE
MW4GB[3'EU2:U%U.MNH&C"6.1V5_FQ]Y!&-^""><\5)J'Q!OK76M&L['7K;4L
MM917)CMTCBNA/(R^8A+[SP,C8"H(Y)SB@#UJ""&U@6"WA2&)!A4C4*JCV JS
M7D&GZ]J\/PQ\#II>J(+S4[Z'3Y[J9?/9 1(7X)^^"F.>AZUC6OC[Q5:Z/%J-
M_J5E<+<6<EP2+41K!Y-_';LQ.XY!1V)SPI''% 'O%%>,S?$#4+W5;BUM_$NF
M:1IL=Y?+'JDL2R1.(%A*19+ $GS')(.2%X[FI+GQQX@77+J.'5M.1_MEQ9)I
M\\>WR(TM3*EV[9WA"P4GC&UP!SU /8J*\.N/B5JL7A1P-;5=9@>X9V-O;M&W
MEP+)M$@D\MERZ\KER#C:"":[3PGK%U?>*M3WR%H;O3-.U(QAB5AEE6165<]
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MJ=I;)ND;-O9!(EZ]6AZ =R:[&N8\=VUQ>?#KQ%9VMN]Q<3Z?/''%&NYG8H0
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MW@P.X]:Q+?\ X2"ZB9;675+=WD$NIVT274]Q;,;51;$E2'=6=97&/E#$9]:
M/9O^$:\1_P#11-8_\!++_P",4?\ "->(_P#HHFL?^ EE_P#&*T-'6\_L2RCO
MII)KI8(Q-)(H5G?:,D@$@'/45M4 <K_PC7B/_HHFL?\ @)9?_&*/^$:\1_\
M11-8_P# 2R_^,5U5% '*_P#"->(_^BB:Q_X"67_QBC_A&O$?_11-8_\  2R_
M^,5U5% '*_\ "->(_P#HHFL?^ EE_P#&*/\ A&O$?_11-8_\!++_ .,5U5%
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M **)K'_@)9?_ !BC_A&O$?\ T436/_ 2R_\ C%=510!RO_"->(_^BB:Q_P"
MEE_\8H_X1KQ'_P!%$UC_ ,!++_XQ7544 <K_ ,(UXC_Z*)K'_@)9?_&*/^$:
M\1_]%$UC_P !++_XQ7544 <K_P (UXC_ .BB:Q_X"67_ ,8H_P"$:\1_]%$U
MC_P$LO\ XQ7544 <K_PC7B/_ **)K'_@)9?_ !BC_A&O$?\ T436/_ 2R_\
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M$KD9&1VR* +M%%% !157SHOM MVD42LI8)D;B!P3CTY'YU:H **** "BBB@
MHJI%/#<*S0RK(JL4)5@0&!P1]0:)KB&WC\RXF2),@;G8 9)P!D^] %NBBB@
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MCQOY)X4 9S6;8^,-:NM#T4^)O%=UX?L&M=08:E#$ ]Q<PW31Q(Q9.3Y0#;<
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
6HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>cvm_ex99img17.jpg
<TEXT>
begin 644 cvm_ex99img17.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %G G # 2(  A$! Q$!_\0
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M;GTD=00OXFA)O9";2W.NHJ".6.:-98W#HX#*P.00>A%3YH&%%%-W  G/3K0
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MBSM4\R63:3M'T')I)7T0-V-;BEKE[[Q9H.FV6F7MW?!8=5D2.TPI9IF<97
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MM)TATI8_-1(8P%VS*PP@!.YF)^E5;Y])\0:EXE\Y-0U#7Y+C[%IL</G*J&-
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M_P!!#4/_  (:@#4HK+_L:/\ Z"&H?^!#4?V-'_T$-0_\"&H U**R_P"QH_\
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M!8- ANM4FDF8JB0S$DX&30!TE%<IM;_GVU__ +^__7HVM_S[:_\ ]_?_ *]
M'5T5RFUO^?;7_P#O[_\ 7HVM_P ^VO\ _?W_ .O0!U=%<IM;_GVU_P#[^_\
MUZ-K?\^VO_\ ?W_Z] '5T5RFUO\ GVU__O[_ /7HVM_S[:__ -_?_KT =717
M*;6_Y]M?_P"_O_UZ-K?\^VO_ /?W_P"O0!U=%<IM;_GVU_\ [^__ %Z-K?\
M/MK_ /W]_P#KT =717)IY/VJ"";^V;<SOL1Y)3MW8SC@^U:/A]IFL)TFFDF,
M5S+&K2-EMH;@$T ;=%%% !1110 4444 %%%% !1110 4444 %%9VHZGI^DV+
MWVIWD5I;(0&EE;:H). /SK,N?&'ANT>[CN-8@C>T95F4DDJ3T'3GWQG'>@"Y
MXD_Y%N[^@_\ 0A6P.E8>O2QS^&+F:%A)&Z*RLIR&!(P16X.E !1110 4444
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MW>=LUGMSQE&SC\Z-NO?\]K+_ +]O_C3VU:W5BOD77!QQ W^%)_;%O_S[W?\
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MKR ULTM5;:Z@NH!-;R"2,Y 8>U6J+-.S ****8!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %9&I65U<W%G<6<T4<EL[-B5"RL"N.Q%:]% &5Y>O_\ /QI__?I_
M_BJ/+U__ )^-/_[]/_\ %5JT4 97EZ__ ,_&G_\ ?I__ (JCR_$'_/S8?]^G
M_P#BJU:* ,=H==D1E>?3V5A@J86((_[ZK)'A&%;(68TC0!;B3S1%]B.T/_>Q
MGK7744 <O_8%Q]N>^^QZ/]K=/+:;[*=[+C&W.>F.*?<:'<7B(EW:Z-.JQ^4H
MDM"P5/[HR>GM72T4 <L/#\GV46PT_1! %V"/[&=H&,8QGT)%7;:RU:SMH[6S
M;3;>",;4CC@954>@ :MRB@#*\OQ!_P _-A_WZ?\ ^*H\OQ!_S\V'_?I__BJU
M:* ,%K'5KF\M9+RYM?*MY?-Q%&P9C@C&2?>IO#__ !ZWG_7Y-_Z%6Q6-X>_X
M]+O_ *_)O_0J -FBBB@ HHHH **** "BBB@ HHHH **** "O)+_XF:M;>*;[
M0$TZSCE61EAEF9A'&JDY,C=#N XQT/!KUNL:3P_H<GVHR:19N;Q@UQNA4^:1
MT+<<XH Q]4UN.\\'PW#6EQ&U[;Q3 ",LJ;B#@MT%=B.E8WB,!?#-VJC "J !
MV^85LCI0 4444 )VK#U0S6ERFJ)'&Z1QF.0,VTX+#D&MPU%)&DT;1R*'1A@J
MPR#2:N)JXJ21R#Y'5OH<T^N<N+74K/5(YM%M+,PRA4G61BFT GYA@<U?M=0D
M>YN;>\6&*2';RLF0P(SWQ2OW$GT9K45&LD<F=CJV/0YJ2J*.;NK>XTFXBNK2
M:YEMVN"TT"J' #9R0 ,]:U;.\AOK<30[MF2N&4J00<$$&KM9+:);^8\D<US%
MO8N52=E7)Z\474E[VC[@:U'-<_)8WEC=V]SIYN+E!N62*6Y."".#\WH:N?;-
M5_Z W_DPM'L[V<6OO2 U*,UD2:AJ4<32-HQPH+'_ $A>U6[>^M[BUBN!*JB1
M ^TL,C(I.$E_5P+U%5/MMF93"+F(R ;BN\9 ]:2.]LY5+1W,3@$J2'!Y'44[
M2[ 7**A^T6Y./.C)_P!X5-2LT 4444P"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *QO#W_ !Z7?_7Y-_Z%6S6-X>_X]+O_ *_)O_0J -FB
MBB@ HHHH **** "BBB@ K UC7)K"6.UL]'OM4N77=LMXP$4?[3L0H^F<UOUY
M1\2&\1:IK5GX7T-+A8=1B N)/O1*N_DD#E<8Y)(!'&#0!W^DZLVJPNSZ?=V$
ML3;9(;J/:P/L1D,/<&MBN7\(V2Z7H-KHYEWSV:E)5,XF*$DG&>P]!@8&!744
M %%%>)ZAX?\ &TWBG7[AK._FTNXN YACN]ID0<($.[L<,?NX QS0!ZIXD_Y%
MN[^@_P#0A6P.E<9J5GK$?A&!;S4L316\2W*B,-YC@C<=U=D* %HHHH ****
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M8+4N[^[_ ()L^8O]X4>8O]X5C?\ ",Z+_P ^[?\ ?U_\:/\ A%]%_P"?5O\
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M?!]A;O/<3%5)S<1M&RY8G;M;D =!GL!7251T]KYK&-M2CABNR/WBP,60'V)
M)J]0 5XK>>/O%47B'6+*2XAL+>.Z:*.1K<2+:1KT9^<Y<X !]>*]JJNT,+;]
MT2G?C=D#YL=,T <OJ6H:I=>#X;B72]IN+>*2;,FWRF)!(VGGBNANKFWL;&:\
MNYD@MH(VEEDD;"HBC)8D]  ,U6\2?\BW=_0?^A"LCXB6MU>?"KQ=8V-O)<W4
M^CWD4,,2EGD=H'"JH'4DD "@"VOC3PFWA9O%"^)--;05ZZB+E/('S;?OYQUX
M^M:EG>6NH6%O?V-PES:W$:RPS1-N21&&58$=00<YKY#T_P"'?C*+PXGP[D\.
M7W_"*2Z4/%#AH6XN_L13[%C'WOM&U]OWN.E;5]J'Q2\-> O["TW1?%?VB[\&
MZ/'IAT^V=DL;J)/])#8_U3XP",9..E 'TA9^)]#O-:U;1X=03[=I,L4-Y&X*
M>4\J!XUR0 Q*D'@FJFJ>./#.CWKV=YKEN+J.[MK&2!"9)(IKC_4*ZJ"5W]B<
M#'-?/'Q$\'^)M1U7QKJD>F^)%BB\0Z%?[M)A;S[B-+1$EDB&T^8T;9(QT8<]
M*T?&&E^/M2US7X])L=6NHX]:\,SZ3)?VKLHV1YED<@<A7P9#V.>E 'T;<:MI
M=KJMEI-QJ$$.H7ZR-:VSR 23B, N57J=H(SCIFM:OF9;CXD-IOA.3[/XF_M.
M'2_$"ZLUQ$[LM\(5\K:P7 0OGRMO!&,9YIFGP?&C1M O?[/U7Q%K.I:IX,AU
M(#5(P19ZD64/#%E0%<(6^0\Y&30!].45XI\!YO%\VG:S_P )-J&OW5NLD7V:
M/7[.6*XB8J?,Q)(J^8I..@^7I7M= !1110 4444 %%%% !1110 4444 ,8!E
M*MR#P16%:PW>GF>&WL1+ 92\>)0-JD#C!Z5T%)Q2:N)JYF_:]4_Z!?\ Y'7_
M  H^U:I_T"__ ".O^%:5%'S%9]S-^UZI_P! O_R.O^%'VO5/^@7_ .1U_P *
MT:*+>86?<S[6^DGNI;>:U,#QJK??# @Y]/I6C5"XTVQN9?.GMP\F-N[D''X5
M1MTDTV]NHX;&9X)&5H]C @<8/4\<TM5N%VMS=Q2UEPZAONTM9+6:!Y%+*7 P
M<=>AK3SQ3W&G<6BBBF,**** "BBB@#G]:_Y#.C?]?)_]%M6[6%K'_(:T;_KX
M/_HMJW:E;LTG\,?3]1]%%%49A1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %8WA[_CTN_P#K\F_]"K9K&\/?\>EW_P!?DW_H
M5 &S1110 4444 %%%% !1110 5YA\6K-E\-Q:M:::MS=QR+$TYC:3R8CDD[0
M0,9QR>F:]/KS_P"(\=Y)X>2.SG5YYKB-(;1[7SA.W)VX]QW;@8H O?#VXDNO
M .DS2"+YXR5\H@J5W''0D XZC)YKLJPO"\=_#X7L8]4LQ9WBQ_O(%" (<]/W
M?R_E6[0 5FR:IID;3I)J-LC6^/-5IE!CSTW<\9]ZTJ\FU7X?ZQ=Z_J6I6L=@
MD,UQY[6LLSNEZQ&T.^1\A4'@#()':@#T+Q)SX;NR.F%_]"%:XZ5QNH:3+:>"
MX;>34;AFM+>*%MK864J0,D$9YKLNU !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!GW5A;W;1M+O#1YVLCE2,
M]>E95UX5L;O4K._>\OUDM"Q54NG"MD8Y&>:Z6DXJ7%/<EQB]T8%M*]A>W4$D
M=Y+#N5HCM:08QS@_6KT>IP2W"V_ES1R,I91)&5R!UK1K&US2[O4;4G3M2;3K
MM498YUC#[<CT-+5+0+<JT-BEKG9=+UYM+CMT\22)<H%W3_9D);'7CWK4TV:2
M?3()IF#2,GS$#&333\@3N[%^BBBJ*.>UC_D.:+_U\G_T6U;R_?:L'6/^0YHO
M_7R?_1;5O+]]JE;FT_ACZ?J/HHHJC$**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ K&\/?\ 'I=_]?DW_H5;-8WA[_CTN_\
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MC0_"CGTK'N+?7&MI%MK^W28J=C- 2 ?SJ*PM?$T9E_M#5+.;.-GEVQ7''/\
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MW/*#'RGD\CU-:E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:I+XPTJUNY+>+3;VTA"K$%>1[AXRY!&[<B@=."/>NS\/_P#(!M?]T_\ H1H
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MNS '<P+_ (51L?#NDVOVC-A9R^=,TR_N%^4'H.E %_\ MK1_^@M9_P#?]?\
M&C^VM'_Z"UG_ -_U_P :/[%T?_H$V?\ WX7_  K-DT/1Y-5@OEM;$+ C1L@A
M3DMC_"@#2_MK1_\ H+6?_?\ 7_&C^VM'_P"@M9_]_P!?\:/[%T?_ *!-G_WX
M7_"L[4/#^CWD*VJV=E#)YB2?ZE,D*P/3\* -'^VM'_Z"UG_W_7_&C^VM'_Z"
MUG_W_7_&FKH^BL-RZ79,#W$"?X4K:1HRC<VEV8'J8%_PH 7^VM'_ .@M9_\
M?]?\:/[:T?\ Z"UG_P!_U_QJCIWAW2+.S%JUA:2NK,Q/D+GEB?3WJ]_8NC_]
M FS_ ._"_P"% !_;6C_]!:S_ ._Z_P"-']M:/_T%K/\ [_K_ (U27P[I']J-
M?#3[,H8O*V>0N,[LYZ5=_L71_P#H$V?_ 'X7_"@ _MK1_P#H+6?_ '_7_&C^
MVM'_ .@M9_\ ?]?\:I7GA[2;A[8K86D?DRB8CR%^8#MTJX-'T8@$:59D'_I@
MO^% "_VUH_\ T%K/_O\ K_C1_;6C_P#06L_^_P"O^-0RZ-HYC93IEDNX;03
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M6$BXY0X((!]16%X1\&>)-%\7MK6L:Q;7T,FEQ6>R.(H8F0C"KR1M'//4YYH
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MVS0 BWUBPCV74+"5BB8D!WL.H'J:O5XMIWPYUY/$6DZV]C8V#Q3;YK6.4-!
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MRVB:V!6%DA4&('J%XX_"@#4KQ[Q)\2->T?6;W3;5M-NP95\J>,96W3+;@^7
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M1R >XSWJ*70]&N!)Y^DVDOFOYDF^!3O?^\>.3[UH*JQHJHH55& !P * //\
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HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>cvm_ex99img16.jpg
<TEXT>
begin 644 cvm_ex99img16.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %& 94# 2(  A$! Q$!_\0
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M#Z-HKYK\3?$;QEX#\0'X=>$]).NMX?TNWN;F\U61I9K_ '9+.9&E3RQP<O\
M/@\8 %6/$7QVUK2_'=K9Z3:6%_I7V^QL;V%K619;5KA5.#<>9L9QN. L;# Y
M:@#Z,HKR?P'XR\:>+_&'BR.\MM%A\.:%K%YI"&(2_:Y'B*;&.24 VL<GJ3T
MQSYGXDUR\U+5?C!J&O>/=4\.ZEX4.-$LK74&M8XD$.^*0Q @3>:^!\P;K@8R
M* /J2BOFR?XU>.M'M-'T74M'L'\2>(]'TJYT-)(9%66YF=8[E)@&XV9+X&W
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M>$]'O-5C(*WL]C$\RD=#O*YX[<U'>>!?!NH:[_;FH>$=&N]6W!OML]C$\V0
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M>!_%%_/8>&_$6D:O=0)YDD-G/'*R+G&2!T&2!75_9K?_ )]X_P#OD5XK\)_
MOBGPKXPOISI<GAKPI]A\B/19=8.I!KDR[C-&Q \I-N1M[DYP*]OH B^S6_\
MS[Q_]\BC[-;_ //O'_WR*EHH B^S6_\ S[Q_]\BC[-;_ //O'_WR*EHH B^S
M6_\ S[Q_]\BC[-;_ //O'_WR*EHH B^S6_\ S[Q_]\BC[-;_ //O'_WR*EHH
M B^S6_\ S[Q_]\BC[-;_ //O'_WR*EHH B^S6_\ S[Q_]\BC[-;_ //O'_WR
M*EHH B^S6_\ S[Q_]\BC[-;_ //O'_WR*EHH B^S6_\ S[Q_]\BC[-;_ //O
M'_WR*EHH B^S6_\ S[Q_]\BC[-;_ //O'_WR*EHH A^SV_\ SPC_ .^14H
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MM,?]V3_OVW^%'VF/^[)_W[;_  H FHJ'[3'_ ')?^_3?X4?:8_[DO_?IO\*
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M\,VMTNM66J)&/)M)TFRW <JP.!^53:7X>9]MQJ"E5ZK#W/U_PKIU554*JA5
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MJ\0GM93&YC?&Y"?0X'N" 1BIFTBQ:QLK%8S':V31M%$APO[O[@/J 0#CU H
MS]!UZ'5(?LTEP&U&)2\R+$R*/F*D(2,.%8%-PSROO72,VU"VTMCL.IK$TOP_
MIVE7\]Y9^<7D!11(Y98D+ERJ#L"S$_EV K?H J")I&#W'0<K&.@^OJ:MT44
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M?_6H\RY_Y]T_[^?_ %J )Z*@\RY_Y]U_[^?_ %JF&<#(P?2@!:*** "BBB@
MHKA&D\4#69Y]$D\O3A.ZR?VQ,K1.V[;B'9EU&[@;CCT6K'B;4-:BL-'L[6 P
M7FHW0AE$4R@Q@1O(RK(PP"=F-V,X)P,XH [.BO-9I-8U33;&XTU=1\G3WN8+
MZW^WB*<R(P'^LP0X!5L<C.1FDFU+6EN=.UZQ-[/HS06\EN&D7;(C1L"D@)W&
M5G:, \]>O7(!Z717)>&=?%^1IMQ]H>[CB,IGEV[;C$C([)@Y"AP0 0#C;75,
M6"$JNX]AG&: !Y$C4L[;15?;)<<R I%_<[M]?\*<D9+"29@[]O1?I_C5F@!
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M$64L1R$$A"CMA16"R[I S*#BF-#!M):,$#GI7X;3QBI1]FX)J_7Y'ZWB<O\
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MC:3S_.\R1R)71C*,?([,I;&3P<=J[=MVP[,;NV>E5X[>WADDDAA1'E.Z1E4
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M_P#/RW_?(IC)Z*@\F?\ Y^6_[Y%'DS_\_+?]\B@">BH/)G_Y^6_[Y%'DS_\
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MQUG['>%A]IU1G:SPV 5M_*"JP['K_M=ZW_$]O;SV$'VI-0Q'<)(DFG(7EB<
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M_GG^IH^RV_\ SS_4T 6**K_9;?\ YY_J:/LMO_SS_4T 6**K_9;?_GG^IJ<
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MOK_.N%+4 *6K[#^"-Q"GP=TA7D .^?C_ +;/7QN6K[+^!?\ R1G1_P#?G_\
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M%C7+G'8#N3[4R2;:VR,;Y/3L/<^E$<.UMTAWR?WNP]AZ4 )Y;3'=)\J=H_\
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MD4G^^O\ .N&+5V7B%O\ B1R?[Z_SJKX2\#ZMXKO$$,316N[#3%?O>RCN?T%
M&%I>DZAK5\EGI]NTTK>G11ZD]A7UQ\+_  SX@T'PQ9:;<Z@RV<&Y@@7&XLQ8
MX[XR:T/ _P -=*\,V,>ZW4R<,0>23ZL>YKT( * %& .U "CIZT444 %%%% !
M1110 4444 %%%% !1110 445BZQ]N_LYWL[S[(Z?.[K;&X<J <A4!Y/3U^E
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
'!1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>cvm_ex99img15.jpg
<TEXT>
begin 644 cvm_ex99img15.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %W 9T# 2(  A$! Q$!_\0
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MY'7OQ6!??$'Q;KFHV7BG3[Q=.OKSX;WNJ"".1_L\4RS [PN3\P4'!.><9XH
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MU@VE^%].LSI[3M:F*$+Y!F4++M]-R@ ^PI8OA]X)ABL8X?"]A&EE;2V=L%B
M\J"7/F1C_9;<<CW-==10!S$?@;P?#L\OP[9+LTTZ,N(AQ9'DV_\ N>U4]4^&
M7P]UJSTZQU;P;I5[;Z;"+>S6:V5O(C'1%/4+[=*[.B@#A_$VB?#O5CH7@_Q9
MINE7"S,_]E:=<H K&*/YA&O3Y4/0=!2:1X?^'.HMJ%KH^FZ5<MI]HWAN[2%
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M#KM^;_CW,9!'.T#'2@#T/5M-\(SZ1I_@76-/M)=.OT%O:Z;)$6C=85#A0,8
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MF9$B8Y9 ?0GM7.2_"GX:SV%MI\W@G2&M;:22:"%K92L3/C?M'8' R!Q7=44
M<C_PK_P7YFBR?\(S8"30L#3'\D;K, Y 0]0,C.*K0?#'X>VVM76K0>"=&CO;
ME)(YI5LTS(L@*N",8^8$@^H)SUKMZ* .7\-^"?"?A$3IX9\.V.DBX(\TVL(0
MOCH">I [#H*ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HJ-Y(XP#(ZH#_>.*;]JM_\ GXB_[[% $U%0_:K?_GXB_P"^Q1]JM_\
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MO%>)K8F0A3]G$BA@$V[@/>KVK>&_&0^"WB&PT7P]XNL8;K7HYM#TA+K=<V\
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M4ZMJM1.W;N>3B<=&-X0>O<]H_P"&EO%7_0%TO\I/_BZ/^&E_%7_0#TS\I/\
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M_P#H5>/FO\'YK]3V,%_$^1Z]534O^07=_P#7%_\ T$U;JIJ7_(+N_P#KB_\
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MBH/(D_Y^I?R7_"CR)/\ GZE_)?\ "@">BH/(D_Y^I?R7_"CR)/\ GZE_)?\
M"@">BH/(D_Y^I?R7_"CR)/\ GZE_)?\ "@">BH/(D_Y^I?R7_"CR)/\ GZE_
M)?\ "@">@]*@\B3_ )^I?R7_  H\B3'_ !]2_DO^% 'QCXZ_Y*'K_P#V$)__
M $8:YRN@\<?+\0/$(+%O^)A/R>_[PUSV:_4\N_W>'HOR/BJOQR]6+129HS7H
M&(M8'B'[]M]&_I6]FL#Q"?GM_HW]*Y:_\-FE'XT8E?:?[.W_ "1RT_Z^I_\
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M/LFG?\_DW_@8_P#\55_RH_[B_E1Y4?\ SS7\J5WW"R[%#[)IW_/Y-_X&/_\
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MFOY4>5'C_5K^5 'Q'X\8-\0_$)!!']H3\C_KHU<Y70^.\#XB^(@!@?VA<?\
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M?_P$D_PI?5JW\C^X?MJ?\R^\]1IU<%X7^)OA#QEJTNF:#?2W%U%"9V5H'0!
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M/=1W*JQ:(MY88?[0 (-9]O%H4^@P:HDOE%XUFW-<*P67S@OV<H>2=O.?QZ4
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MD:59<K4;FM+W]3W;]F,D_$C52>3_ &8__HV.OKON:^1/V8?^2C:I_P!@U_\
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MNR_^BTJ]7 SJ16\VX_Y]6_[[6CS;C_GU;_OM:LT4AE;S;C_GU;_OM:/-N/\
MGU;_ +[6K-% %;S;C_GU;_OM:/-N/^?5O^^UJS10!6\VX_Y]6_[[6E\Z?'_'
MHW_?2_XU8H/2@#X5\>,3\1_$A9=I_M*XXZ_\M&KFLUT?Q /_ !<GQ+_V$KC_
M -&-7,YK]*P/\"/HOR/D*OQOU'YHS3,T9KK,1^:[7P,W[F__ -Y/Y&N'S7:>
M!S^YO_\ >3^1KR<U_P!WE\OT.[ _QX_/\CM-U&ZHMU&ZO@#Z<EW4;JBW4;J
M*FMM_P 2"]_ZY&O-R:]$UIO^)#>_]<S7G!- 'K?P!=E^)-P5C+G^SY> 0/XT
MKZA\VX_Y]6_[[6OE[]GL_P#%S+C_ +!\O_H<=?55 %;S;C_GU;_OM:/-N/\
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MV#]GD_\ %S;C_L'R_P#H<=?5E?*/[/!_XN=<?]@Z7_T..OJZ@ HHHH ****
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MW?:1_P \9O\ OV:/M(_YXS?]^S7J_P!LUNR.+^SZ?=GPC_P@'C7_ *%C4?\
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M@?\ /&7_ +]FO8CFM6,5%):'G/ TV[W9\(?\*_\ &O\ T+&H_P#?DT?\*_\
M&O\ T+&H_P#?DU]W_:?^F,W_ '[-'VG_ *8S?]^S6G]L5NR%_9]/NSX0_P"%
M?^-?^A8U'_OR:W?#_A#Q58)<"Z\.:DA<J5Q;DYQFOM#[2O\ SQF_[]FC[0/^
M>,W_ '[-85\SJUZ;IS2LS2E@X4I*46SY*_X1_P 0?] #4_\ P%:C_A'_ !!_
MT -3_P# 5J^N?M0_YXS?]^S1]J'_ #QF_P"_9KRCN/D;_A'_ !!_T -3_P#
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M^I-+/MW22-"8B#@ 8P<\ 5S_ (R\/ZY?:EJ,/AZ'48TUFV$-W)'<6ZVS,%*
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M#MOSGU'[QOTJC#X'T93=&\GU#4OM%O):?Z=>23>5%)C>J9/RYP.>O YKKJ*
M..;P1IK16(:^U7[39*\:W2W\BS21LP8QNX.2N57CM@8K)UKP3,EKI]KX;M=K
M6ULUF9WU.:V;RLY"OY:DR+DDX)!]#R:]'HH Y*#P?IXT/3M-O&DF:STQ]+\Q
M&V!HW15<X[$[!CTJ?4/#.F7@9I+?[0ZZ?)IRPRR$1O$VTE6QSU1?F'(KIJ*
M/-/#_@O5(=1O;S6+B>#SK1;.,1:I-<S( ^_=YS!2O8 */7.<UUNA^';'03<O
M;S75U<714S7-Y.TTLFT84%CV )P/>MZB@ HHHH **** "BBB@ HHHH ****
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J1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>cvm_ex99img10.jpg
<TEXT>
begin 644 cvm_ex99img10.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %T B0# 2(  A$! Q$!_\0
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MTM<QXF_Y"WA?_L)-_P"D\U)@;.ZC=46ZC=699+NHW5%NHW4 3;J7=4&ZEW4
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M/B'6KC1;&UN+6"&66YN4ME:XF\J*,MGYG;G XQQU)%7-+N;^ZM6DU'[#YH?
M^Q3&5,>Y('/M6O4YI?"7-'_Y! _ZZ2?^AFM45EZ/_P @D?\ 723_ -#-:@K"
M7Q,Z:7PKT0ZBBBD;!1110 4444 %%%% !1110 4444 %%%% !7+^+/\ D(>&
M_P#L('_T1+745RWB[_C^\.?]A _^B):3 FW4;JBW4;JS+)=U+NJ'=1NH GW4
M;JAW4NZ@"7=1NJ+=1NH EW4;JBW4;J )MU&ZH=U&Z@";=U^AIG@;_D1=*]XB
M?_'C32WR-_NG^5.\#_\ (B:/[VX-5$3.CHHHJR0HHHH **** "BBB@ HHHH
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M=5?&B:@?^G:3_P!!-=]H(V^&=*'I:1?^@"FA,TJ***H04444 %%%% !1110
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M'Z5Z_8C&GVH_Z9+_ "%4A,LT444Q!1110 4444 %%%% !1110 4444 %%%%
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M\+^-O"L-KI>L>*--U32+6 Q10P:<8)=V<@E]Y'KQBO1J "BBB@ IC-M4M@G
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MC=46ZC=0!+NHW5%NHW4 2[J-U1;J-U %37&_XD5U[A1_X^*]W P *\#UQO\
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M5PGS2Y;&<Z7)'FN>P>?[UD:Q+NU+0A_T^-_Z)>I?/]ZS=0EW:MH8_P"GMO\
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MUX(U"/[?+IMW]K?45B"9GYVQQX 3KP1N!)/4DXZ5Z+0 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&$![MVJ_7!^+M1\Z\6QC;Y(>6]VH A_X2[5?6/\ [YH_X2[5?6/_ +YKGJ*
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MHHHH **** "BBB@ HHHH **** *\MS)9ZGHUQ%C>FHPD9&1U->H?\)=JF?\
MEG_WS7E-]S?:,/74(_ZUVE '0_\ "7:KZQ_]\T?\)=JOK'_WS7/44 =#_P )
M=JOK'_WS1_PEVJ^L?_?-<]10!T/_  EVJ^L?_?-'_"7:KZQ_]\USU% '0_\
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M\O\ X4?6Z7\R^\/JE;^1_<1=JV?"7_([Z3_OR?\ HMJR_LUU_P ^ES_WY?\
MPK6\,QRV_B_3)Y[>>.)'<L[0N O[MASQ7F8^O3E1FE);=STLNH5(UH-Q>_8]
MEHJE_:=A_P _'_CC?X4?VG8?\_'_ (XW^%?GI^A%VBJ7]IV'_/Q_XXW^%']I
MV'_/Q_XXW^% %VBJ7]IV'_/Q_P".-_A1_:=A_P _'_CC?X4 7:*I?VG8?\_'
M_CC?X4?VG8?\_'_CC?X4 7:*I?VG8?\ /Q_XXW^%']IV'_/Q_P".-_A0!=HJ
ME_:=A_S\?^.-_A1_:=A_S\?^.-_A0 7?.J:&/^G]/_06KLZXF*1-2\1:%;V.
M^XD%YO*HC< 1MSTZ5Z%_9>H_\^<O_?)H IT5<_LO4?\ GSE_[Y-']EZC_P ^
M<O\ WR: *=%7/[+U'_GSE_[Y-']EZC_SYR_]\F@"G15S^R]1_P"?.7_ODT?V
M7J/_ #YR_P#?)H IT5<_LO4?^?.7_ODT?V7J/_/G+_WR: .J\(ZCYEN^GR-\
MT?S)GT[BNMKS/3K?5-/U"&Z2SE^1N1M/([UZ2C!T#@$ C/- #Z*** "BBB@
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MGT4 ,\N/^XOY4>7'_<7\J?10 T*J]% ^@IU%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
; %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Submission<br></strong></div></th>
<th class="th"><div>Aug. 22, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissionLineItems', window );"><strong>Submission [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0000725363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">CEL-SCI Corporation<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FormTp', window );">Form Type</a></td>
<td class="text">S-8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissnTp', window );">Submission Type</a></td>
<td class="text">S-8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeExhibitTp', window );">Fee Exhibit Type</a></td>
<td class="text">EX-FILING FEES<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OffsetTableNa', window );">Offset Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CombinedProspectusTableNa', window );">Combined Prospectus Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_CombinedProspectusTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_CombinedProspectusTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeExhibitTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeExhibitTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:feeExhibitTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FormTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FormTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissnTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissnTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Offerings - Offering: 1<br></strong></div></th>
<th class="th">
<div>Aug. 22, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_AmtSctiesRegd', window );">Amount Registered</a></td>
<td class="nump">133,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxOfferingPricPerScty', window );">Proposed Maximum Offering Price per Unit</a></td>
<td class="nump">13.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 1,738,675<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_AmtSctiesRegd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of securities being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_AmtSctiesRegd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxAggtOfferingPric">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum aggregate offering price for the offering that is being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxAggtOfferingPric</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative100TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxOfferingPricPerScty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum offering price per share/unit being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxOfferingPricPerScty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal4lItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Type of securities: "Asset-backed Securities", "ADRs/ADSs", "Debt", "Debt Convertible into Equity", "Equity", "Face Amount Certificates", "Limited Partnership Interests", "Mortgage Backed Securities", "Non-Convertible Debt", "Unallocated (Universal) Shelf", "Exchange Traded Vehicle Securities", "Other"</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_Rule457oFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 457<br> -Subsection o<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_Rule457oFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Securities, 424I - Securities, 424I: 1<br></strong></div></th>
<th class="th">
<div>Aug. 22, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Scties424iTable', window );"><strong>Securities, 424I Table</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stock, Preferred Stock, Rights and Warrants<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">153.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 266.19<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of registration fee (amount due after offsets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTitl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The title of the class of securities being registered (for each class being registered).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTitl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_PrevslyPdFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_PrevslyPdFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_Scties424iTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_Scties424iTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_Scties424iAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_Scties424iAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fees Summary<br></strong></div></th>
<th class="th">
<div>Aug. 22, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesSummaryLineItems', window );"><strong>Fees Summary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOfferingAmt', window );">Total Offering</a></td>
<td class="nump">$ 1,738,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlFeeAmt', window );">Total Fee Amount</a></td>
<td class="nump">266.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_NetFeeAmt', window );">Net Fee</a></td>
<td class="nump">$ 266<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesSummaryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesSummaryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_NetFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_NetFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOfferingAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOfferingAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>19</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="cvm_ex107.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995210 - Document - Submission</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/submissionTable</Role>
      <ShortName>Submission</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cvm_ex107.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995211 - Document - Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesOfferingTable</Role>
      <ShortName>Offerings</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cvm_ex107.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995214 - Document - Securities, 424I</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/securities424iTable</Role>
      <ShortName>Securities, 424I</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cvm_ex107.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995215 - Document - Fees Summary</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesSummaryTable</Role>
      <ShortName>Fees Summary</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="EX-FILING FEES" original="cvm_ex107.htm">cvm_ex107.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="2">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="17">http://xbrl.sec.gov/ffd/2024q2</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>27
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cvm_ex107.htm": {
   "dts": {
    "inline": {
     "local": [
      "cvm_ex107.htm"
     ]
    },
    "schema": {
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/deprecated-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ffd/2024q2/ffd-2024q2.xsd"
     ]
    }
   },
   "keyStandard": 19,
   "keyCustom": 0,
   "axisStandard": 2,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/ffd/2024q2": 2,
    "http://xbrl.sec.gov/dei/2024": 1
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 107,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ffd/2024q2": 17,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/ffd/role/document/submissionTable",
     "longName": "995210 - Document - Submission",
     "shortName": "Submission",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2025-08-22to2025-08-22",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_ex107.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-08-22to2025-08-22",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_ex107.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
     "longName": "995211 - Document - Offerings",
     "shortName": "Offerings",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "OfferingAxis_From2025-08-22to2025-08-22",
      "name": "ffd:Rule457oFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_ex107.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "OfferingAxis_From2025-08-22to2025-08-22",
      "name": "ffd:Rule457oFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_ex107.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ffd/role/document/securities424iTable",
     "longName": "995214 - Document - Securities, 424I",
     "shortName": "Securities, 424I",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "3",
     "firstAnchor": {
      "contextRef": "Scties424iAxis_From2025-08-22to2025-08-22",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_ex107.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Scties424iAxis_From2025-08-22to2025-08-22",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_ex107.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable",
     "longName": "995215 - Document - Fees Summary",
     "shortName": "Fees Summary",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2025-08-22to2025-08-22",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_ex107.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-08-22to2025-08-22",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_ex107.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ffd_AggtRedRpPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "AggtRedRpPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtRedRpPricPrrFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "AggtRedRpPricPrrFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Prior Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, Prior FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtSalesPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "AggtSalesPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Sales Price, Fiscal Year",
        "terseLabel": "Aggregate Sales Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtRedCdts": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "AmtRedCdts",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Redemption Credits",
        "terseLabel": "Redemption Credits"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtSctiesRcvd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "AmtSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Received",
        "terseLabel": "Amount of Securities Received",
        "documentation": "Amount of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_AmtSctiesRegd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "AmtSctiesRegd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Registered",
        "terseLabel": "Amount Registered",
        "documentation": "The amount of securities being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CeasedOprsDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "CeasedOprsDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ceased Operations Date",
        "terseLabel": "Ceased Operations Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CfwdFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "CfwdFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Form Type",
        "terseLabel": "Carry Forward Form Type",
        "documentation": "The Form Type of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrevslyPdFee": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "CfwdPrevslyPdFee",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Previously Paid Fee",
        "terseLabel": "Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward",
        "documentation": "The fee previously paid in connection with the securities being brought forward from the prior shelf registration statement on which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "CfwdPrrFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Prior Effective Date",
        "terseLabel": "Carry Forward Initial Effective Date",
        "documentation": "The initial effective date of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "CfwdPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward File Number",
        "terseLabel": "Carry Forward File Number",
        "documentation": "The EDGAR File Number of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). If the prior registration statement has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CmbndPrspctsItemAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "CmbndPrspctsItemAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Item [Axis]",
        "terseLabel": "Combined Prospectus",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different references to earlier prospectuses on a single fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "CmbndPrspctsLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Line Items]",
        "terseLabel": "Combined Prospectus:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "CmbndPrspctsTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Table]",
        "terseLabel": "Combined Prospectus Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CombinedProspectusTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "CombinedProspectusTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Table [N/A]",
        "terseLabel": "Combined Prospectus Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CshPdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "CshPdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid by Registrant in Transaction",
        "terseLabel": "Cash Consideration Paid",
        "documentation": "Amount of cash consideration paid by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ffd_CshRcvdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "CshRcvdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Received by Registrant in Transaction",
        "terseLabel": "Cash Consideration Received",
        "documentation": "Amount of cash consideration received by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "ffd_FeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "FeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Amount",
        "terseLabel": "Amount of Registration Fee",
        "documentation": "Total amount of registration fee (amount due after offsets)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeExhibitTp": {
     "xbrltype": "feeExhibitTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "FeeExhibitTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Exhibit Type",
        "terseLabel": "Fee Exhibit Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FeeIntrstAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "FeeIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Interest Amount",
        "terseLabel": "Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "FeeNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note",
        "terseLabel": "Fee Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNoteMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "FeeNoteMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note Maximum Aggregate Offering Price",
        "terseLabel": "Fee Note MAOP"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "FeeRate",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Rate",
        "terseLabel": "Fee Rate",
        "documentation": "The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesOthrRuleFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "FeesOthrRuleFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees, Other Rule [Flag]",
        "terseLabel": "Other Rule",
        "documentation": "Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesSummaryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "FeesSummaryLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees Summary [Line Items]",
        "terseLabel": "Fees Summary:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FnlPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "FnlPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final Prospectus [Flag]",
        "terseLabel": "Final Prospectus"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FormTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "FormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Form Type",
        "terseLabel": "Form Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_GnlInstrIIhiFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "GnlInstrIIhiFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Instruction II.H,I [Flag]",
        "terseLabel": "General Instruction II.H,I"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrCity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "IssrBizAdrCity",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, City",
        "terseLabel": "City"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStatOrCtryCd": {
     "xbrltype": "stateOrCountryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "IssrBizAdrStatOrCtryCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, State or Country Code",
        "terseLabel": "State or Country Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "IssrBizAdrStrt1",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 1",
        "terseLabel": "Street 1"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt2": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "IssrBizAdrStrt2",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 2",
        "terseLabel": "Street 2"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrZipCd": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "IssrBizAdrZipCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Zip Code",
        "terseLabel": "Zip Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrNm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "IssrNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Name",
        "terseLabel": "Issuer Name"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_MaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "MaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum Aggregate Offering Price",
        "documentation": "The maximum aggregate offering price for the offering that is being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_MaxOfferingPricPerScty": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "MaxOfferingPricPerScty",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Offering Price per Security",
        "terseLabel": "Proposed Maximum Offering Price per Unit",
        "documentation": "The maximum offering price per share/unit being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetFeeAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "NetFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Fee Amount",
        "terseLabel": "Net Fee"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetSalesAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "NetSalesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Sales Amount",
        "terseLabel": "Net Sales"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvDsclsr": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "NrrtvDsclsr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure",
        "terseLabel": "Narrative Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "NrrtvMaxAggtAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Amount",
        "terseLabel": "Narrative - Max Aggregate Offering Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "NrrtvMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Price",
        "terseLabel": "Narrative - Max Aggregate Offering Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OfferingAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Axis]",
        "terseLabel": "Offering",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different security offerings on a single fee bearing submission."
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OfferingLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Line Items]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OfferingNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Note",
        "terseLabel": "Offering Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OfferingSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Title",
        "terseLabel": "Security Class Title",
        "documentation": "The title of the class of securities being registered (for each class being registered)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OfferingSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Type",
        "terseLabel": "Security Type",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OfferingTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Table]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OfferingTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Table [N/A]",
        "terseLabel": "Offering Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset [Axis]",
        "terseLabel": "Offset",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different offsets as applied to a fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetClmInitlFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetClmInitlFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claim Initial Filing Date",
        "terseLabel": "Initial Filing Date",
        "documentation": "The initial filing date of the earlier registration statement with which the earlier (offsetting) fee was paid for a claimed offset. If the offset fee was paid with an amendment, do not provide the amendment date under this element; instead, provide the date of the initial filing (i.e. the \"parent\" filing) ."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Amount",
        "terseLabel": "Fee Offset Claimed",
        "documentation": "The amount of offsetting fees being claimed."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdInd": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetClmdInd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Indicator",
        "terseLabel": "Offset Claimed"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetExpltnForClmdAmt": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetExpltnForClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Explanation for Claimed Amount",
        "terseLabel": "Explanation for Claimed Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetLineItems",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset:",
        "label": "Offset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Note",
        "terseLabel": "Offset Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetPrrFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetPrrFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Fee Amount",
        "terseLabel": "Fee Paid with Fee Offset Source",
        "documentation": "The fee prevoiusly paid from which an offset is being derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior File Number",
        "terseLabel": "File Number",
        "documentation": "The EDGAR File Number of the earlier registration statement with which the earlier (offsetting) fee was paid. If the offset filing for the offset has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFilerNm": {
     "xbrltype": "filerNameItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetPrrFilerNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Filer Name",
        "terseLabel": "Registrant or Filer Name",
        "documentation": "The name of the registrant that filed the earlier registration statement with which the earlier (offsetting) fee was paid."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetPrrFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Form Type",
        "terseLabel": "Form or Filing Type",
        "documentation": "The Form Type of the offset filing."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrNbOfUnsoldScties": {
     "xbrltype": "nonNegativeIntegerItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetPrrNbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Number of Securities",
        "terseLabel": "Unsold Securities Associated with Fee Offset Claimed",
        "documentation": "The number of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetPrrSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Title",
        "terseLabel": "Security Title Associated with Fee Offset Claimed",
        "documentation": "The title of the class of securities from which offset fees were derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetPrrSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Type",
        "terseLabel": "Security Type Associated with Fee Offset Claimed",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrUnsoldOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetPrrUnsoldOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Offering Amount",
        "terseLabel": "Unsold Aggregate Offering Amount Associated with Fee Offset Claimed",
        "documentation": "The aggregate offering amount of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetSrcFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetSrcFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Source Filing Date",
        "terseLabel": "Filing Date",
        "documentation": "The filing date of the earlier registration statement with which the earlier (offsetting) fee was paid in an offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset Payment:",
        "label": "Offset [Table]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "OffsetTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Table [N/A]",
        "terseLabel": "Offset Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_PrevslyPdFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "PrevslyPdFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Previously Paid [Flag]",
        "terseLabel": "Fee Previously Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RegnFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "RegnFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration File Number",
        "terseLabel": "Registration File Number"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RptgFsclYrEndDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "RptgFsclYrEndDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reporting Fiscal Year End Date",
        "terseLabel": "Reporting FY End Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule011Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 0-11 [Flag]",
        "terseLabel": "Rule 0-11"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011a2OffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule011a2OffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 0-11(a)(2) Offset",
        "label": "Rule 0-11(a)(2) Offset [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule415a6Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule415a6Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 415(a)(6) [Flag]",
        "terseLabel": "Rule 415(a)(6)",
        "documentation": "Checkbox indicating whether filer is claiming a 415(a)(6) carryforward."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_Rule429AggtOfferingAmt": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule429AggtOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Aggregate Offering Amount",
        "terseLabel": "Maximum Aggregate Offering Price of Securities Previously Registered",
        "documentation": "The maximum aggregate offering amount of unsold securities registered on the prior registration statement that are carried forward under Rule 429. Only applicable if 457(o) was used in the fee calculation for the prior registration statement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429CmbndPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule429CmbndPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Combined Prospectus [Flag]",
        "terseLabel": "Rule 429",
        "documentation": "Checkbox indicating whether filer is using a combined prospectus under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule429EarlierFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier File Number",
        "terseLabel": "File Number",
        "documentation": "The Securities Act File Number of the earlier effective registration statement(s) from which securities may be offered and sold using the combined prospectus pursuant to Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule429EarlierFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier Form Type",
        "terseLabel": "Form Type",
        "documentation": "The Form Type of the earlier registration statement from which unsold securities are carried forward under Rule 429. This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429InitlFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule429InitlFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Initial Effective Date",
        "terseLabel": "Initial Effective Date",
        "documentation": "The filing date of the earlier registration statement from which unsold securities are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429NbOfUnsoldScties": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule429NbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Number Of Unsold Securities",
        "terseLabel": "Amount of Securities Previously Registered",
        "documentation": "The number of securities registered on the prior registration statement that are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429PrspctsNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule429PrspctsNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Prospectus Note",
        "terseLabel": "Combined Prospectus Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule429SctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Title",
        "terseLabel": "Security Class Title"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule429SctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Type",
        "terseLabel": "Security Type"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule457aFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule457aFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(a) [Flag]",
        "terseLabel": "Rule 457(a)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ffd_Rule457bOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule457bOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(b) Offset [Flag]",
        "terseLabel": "Rule 457(b) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(b) or 0-11(a)(2)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ffd_Rule457fFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule457fFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(f) [Flag]",
        "terseLabel": "Rule 457(f)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_Rule457oFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule457oFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(o) [Flag]",
        "terseLabel": "Rule 457(o)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ffd_Rule457pOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule457pOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(p) Offset [Flag]",
        "terseLabel": "Rule 457(p) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(p)."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ffd_Rule457rFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule457rFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(r) [Flag]",
        "terseLabel": "Rule 457(r)"
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ffd_Rule457sFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule457sFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(s) Flag",
        "terseLabel": "Rule 457(s)"
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ffd_Rule457uFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Rule457uFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(u) [Flag]",
        "terseLabel": "Rule 457(u)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(u) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ffd_Scties424iAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Scties424iAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Axis]",
        "terseLabel": "Securities, 424I"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Scties424iLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Line Items]",
        "terseLabel": "Securities, 424I:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Scties424iTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Table]",
        "terseLabel": "Securities, 424I Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Securities424iTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "Securities424iNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities 424I [N/A]",
        "terseLabel": "Securities 424I N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "SubmissionLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission [Line Items]",
        "terseLabel": "Items"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissnTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "SubmissnTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission Type",
        "terseLabel": "Submission Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TermntnCmpltnWdrwl": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "TermntnCmpltnWdrwl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination / Completion / Withdrawal Statement",
        "terseLabel": "Termination / Withdrawal Statement"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TtlFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "TtlFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee Amount",
        "terseLabel": "Total Fee Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlFeeAndIntrstAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "TtlFeeAndIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee and Interest Amount",
        "terseLabel": "Total Fee and Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "TtlOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offering Amount",
        "terseLabel": "Total Offering"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOffsetAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "TtlOffsetAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offset Amount",
        "terseLabel": "Total Offset Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlPrevslyPdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "TtlPrevslyPdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Previously Paid Amount",
        "terseLabel": "Previously Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlTxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "TtlTxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Transaction Valuation",
        "terseLabel": "Total Transaction Valuation"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "TxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Valuation",
        "terseLabel": "Transaction Valuation"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_ValSctiesRcvd": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "ValSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received",
        "terseLabel": "Value of Securities Received",
        "documentation": "Value of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_ValSctiesRcvdPerShr": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2024q2",
     "localname": "ValSctiesRcvdPerShr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received, Per Share",
        "terseLabel": "Value of Securities Received, Per Share",
        "documentation": "Value per share of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form). This is included in the explanation of 457(f) fee calculation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "415",
   "Subsection": "a"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "429"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "f"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "o"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "p"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "r"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "s"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "u"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Subsection": "f",
   "Section": "457"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>28
<FILENAME>0001654954-25-010214-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001654954-25-010214-xbrl.zip
M4$L#!!0    (  B"'5MY7&?#E0H  '"F   -    8W9M7V5X,3 W+FAT;>U=
MZW/B.!+_?G^%SC.[LULUCFW>&,)6AI!9:B<D%=B[N?LR)=LR:,</1I83N+_^
M6@+S")#-@R1 E*I4;/3H[E^W6MUR!]=_&X4!NB8LH7%T_,$Z,C\@$KFQ1Z/^
M\8>3;K/=_O!;XQ_U 8=NT#5*;#HZU@:<#VW#N+FY.1HY+#B*6=_(F5;>H%%
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M'SG@8=#X/U!+ 0(4 Q0    (  B"'5MY7&?#E0H  '"F   -
K  "  0    !C=FU?97@Q,#<N:'1M4$L%!@     !  $ .P   , *      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>cvm_ex107_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2024q2"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2024q2/ffd-2024q2.xsd"
      xlink:type="simple"/>
    <context id="From2025-08-22to2025-08-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2025-08-22</startDate>
            <endDate>2025-08-22</endDate>
        </period>
    </context>
    <context id="Scties424iAxis_From2025-08-22to2025-08-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:Scties424iAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-22</startDate>
            <endDate>2025-08-22</endDate>
        </period>
    </context>
    <context id="OfferingAxis_From2025-08-22to2025-08-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-22</startDate>
            <endDate>2025-08-22</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <ffd:FeeExhibitTp contextRef="From2025-08-22to2025-08-22" id="ixv-638">EX-FILING FEES</ffd:FeeExhibitTp>
    <ffd:SubmissnTp contextRef="From2025-08-22to2025-08-22" id="ixv-639">S-8</ffd:SubmissnTp>
    <dei:EntityCentralIndexKey contextRef="From2025-08-22to2025-08-22" id="ixv-640">0000725363</dei:EntityCentralIndexKey>
    <ffd:FormTp contextRef="From2025-08-22to2025-08-22" id="fid_4138e7ac">S-8</ffd:FormTp>
    <dei:EntityRegistrantName contextRef="From2025-08-22to2025-08-22" id="ixv-675">CEL-SCI Corporation</dei:EntityRegistrantName>
    <ffd:PrevslyPdFlg
      contextRef="Scties424iAxis_From2025-08-22to2025-08-22"
      id="fid_49f539db">true</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp
      contextRef="OfferingAxis_From2025-08-22to2025-08-22"
      id="fid_035dd25f">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl
      contextRef="Scties424iAxis_From2025-08-22to2025-08-22"
      id="fid_cf6847f3">Common Stock, Preferred Stock, Rights and Warrants</ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg
      contextRef="OfferingAxis_From2025-08-22to2025-08-22"
      id="fid_889bc4b0">true</ffd:Rule457oFlg>
    <ffd:AmtSctiesRegd
      contextRef="OfferingAxis_From2025-08-22to2025-08-22"
      decimals="0"
      id="fid_51112b40"
      unitRef="USD">133334</ffd:AmtSctiesRegd>
    <ffd:MaxOfferingPricPerScty
      contextRef="OfferingAxis_From2025-08-22to2025-08-22"
      decimals="INF"
      id="fid_6855bb21"
      unitRef="USD">13.04</ffd:MaxOfferingPricPerScty>
    <ffd:MaxAggtOfferingPric
      contextRef="OfferingAxis_From2025-08-22to2025-08-22"
      decimals="INF"
      id="fid_0b5d7c57"
      unitRef="USD">1738675</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="Scties424iAxis_From2025-08-22to2025-08-22"
      decimals="INF"
      id="fid_411f2a2b"
      unitRef="Pure">1.5310</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="Scties424iAxis_From2025-08-22to2025-08-22"
      decimals="INF"
      id="fid_79d20ccb"
      unitRef="USD">266.19</ffd:FeeAmt>
    <ffd:TtlOfferingAmt
      contextRef="From2025-08-22to2025-08-22"
      decimals="INF"
      id="fid_08160b3f"
      unitRef="USD">1738675</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt
      contextRef="From2025-08-22to2025-08-22"
      decimals="INF"
      id="fid_cc560f25"
      unitRef="USD">266.19</ffd:TtlFeeAmt>
    <ffd:NetFeeAmt
      contextRef="From2025-08-22to2025-08-22"
      decimals="0"
      id="fid_8dd90725"
      unitRef="USD">266</ffd:NetFeeAmt>
    <ffd:OffsetTableNa contextRef="From2025-08-22to2025-08-22" id="fid_c7fc5739">N/A</ffd:OffsetTableNa>
    <ffd:CombinedProspectusTableNa contextRef="From2025-08-22to2025-08-22" id="fid_759948be">N/A</ffd:CombinedProspectusTableNa>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
